Document and Entity Information
Document and Entity Information - shares | 3 Months Ended | |
Mar. 31, 2021 | Apr. 27, 2021 | |
Cover [Abstract] | ||
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Period End Date | Mar. 31, 2021 | |
Document Transition Report | false | |
Entity File Number | 001-34746 | |
Entity Registrant Name | R1 RCM INC. | |
Entity Incorporation, State or Country Code | DE | |
Entity Tax Identification Number | 02-0698101 | |
Entity Address, Address Line One | 401 North Michigan Avenue | |
Entity Address, City or Town | Chicago | |
Entity Address, State or Province | IL | |
Entity Address, Postal Zip Code | 60611 | |
City Area Code | 312 | |
Local Phone Number | 324-7820 | |
Title of 12(b) Security | Common stock, par value $0.01 per share | |
Trading Symbol | RCM | |
Security Exchange Name | NASDAQ | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filter Category | Large Accelerated Filer | |
Smaller Reporting Company | false | |
Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding (in shares) | 261,589,352 | |
Amendment Flag | false | |
Document Fiscal Year Focus | 2021 | |
Document Fiscal Period Focus | Q1 | |
Entity Central Index Key | 0001472595 | |
Current Fiscal Year End Date | --12-31 |
Consolidated Balance Sheets
Consolidated Balance Sheets - USD ($) $ in Millions | Mar. 31, 2021 | Dec. 31, 2020 |
Current assets: | ||
Cash and cash equivalents | $ 103.5 | $ 173.8 |
Accounts receivable, net of $3.8 million and $3.7 million allowance | 97.6 | 91.3 |
Accounts receivable, net of $0.1 million and $0.1 million allowance - related party | 31.8 | 30.9 |
Prepaid expenses and other current assets | 65.7 | 59.4 |
Total current assets | 298.6 | 355.4 |
Property, equipment and software, net | 89 | 93.7 |
Operating lease right-of-use assets | 59.8 | 57.8 |
Intangible assets, net | 166.7 | 171.1 |
Goodwill | 375.5 | 375.3 |
Non-current deferred tax assets | 68.5 | 73.7 |
Non-current portion of restricted cash equivalents | 0.5 | 1 |
Other assets | 75.9 | 61 |
Total assets | 1,134.5 | 1,189 |
Current liabilities: | ||
Accounts payable | 22.8 | 18.2 |
Current portion of customer liabilities | 23 | 16.7 |
Current portion of customer liabilities - related party | 10.6 | 15.3 |
Accrued compensation and benefits | 61.2 | 51.9 |
Current portion of operating lease liabilities | 11.8 | 12.2 |
Current portion of long-term debt | 35.5 | 32.3 |
Other accrued expenses | 56.6 | 59.7 |
Total current liabilities | 221.5 | 206.3 |
Non-current portion of customer liabilities - related party | 15.4 | 16.3 |
Non-current portion of operating lease liabilities | 68.7 | 71 |
Long-term debt | 510.2 | 519.7 |
Other non-current liabilities | 35.1 | 36.3 |
Total liabilities | 850.9 | 849.6 |
8.00% Series A convertible preferred stock, par value $0.01, no shares authorized, issued and outstanding as of March 31, 2021; 370,000 shares authorized, 288,497 shares issued and outstanding as of December 31, 2020 (aggregate liquidation value of $294.3) | 0 | 251.5 |
Stockholders’ equity: | ||
Common stock, $0.01 par value, 500,000,000 shares authorized, 277,972,263 shares issued and 261,301,541 shares outstanding at March 31, 2021; 137,812,559 shares issued and 121,144,038 shares outstanding at December 31, 2020 | 2.8 | 1.4 |
Additional paid-in capital | 562.1 | 393.7 |
Accumulated deficit | (135.7) | (161.5) |
Accumulated other comprehensive loss | (6.4) | (6.5) |
Treasury stock, at cost, 16,670,722 shares as of March 31, 2021; 16,668,521 shares as of December 31, 2020 | (139.2) | (139.2) |
Total stockholders’ equity | 283.6 | 87.9 |
Total liabilities and stockholders’ equity | $ 1,134.5 | $ 1,189 |
Consolidated Balance Sheets (Pa
Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Millions | 3 Months Ended | 12 Months Ended |
Mar. 31, 2021 | Dec. 31, 2020 | |
Accounts receivable, allowance | $ 3.8 | $ 3.7 |
Common stock, par value (in dollars per share) | $ 0.01 | $ 0.01 |
Common stock, shares authorized (in shares) | 500,000,000 | 500,000,000 |
Common stock, shares issued (in shares) | 277,972,263 | 137,812,559 |
Common stock, shares outstanding (in shares) | 261,301,541 | 121,144,038 |
Treasury stock, shares (in shares) | 16,670,722 | 16,668,521 |
Redeemable Convertible Preferred Stock | ||
Preferred stock, dividend rate (percentage) | 8.00% | 8.00% |
Preferred stock, par value (in dollars per share) | $ 0.01 | $ 0.01 |
Preferred stock, shares authorized (in shares) | 0 | 370,000 |
Preferred stock, shares issued (in shares) | 0 | 288,497 |
Preferred stock, shares outstanding (in shares) | 0 | 288,497 |
Preferred stock, aggregate liquidation value | $ 294.3 | |
Related Party | ||
Accounts receivable, allowance | $ 0.1 | $ 0.1 |
Consolidated Statements of Oper
Consolidated Statements of Operations and Comprehensive Income (Unaudited) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Income Statement [Abstract] | ||
Net services revenue ($215.5 million and $208.4 million for the three months ended March 31, 2021 and 2020, from related party, respectively) | $ 342.6 | $ 320.5 |
Operating expenses: | ||
Cost of services | 267.2 | 253.9 |
Selling, general and administrative | 25.6 | 25.5 |
Other expenses | 13 | 8.7 |
Total operating expenses | 305.8 | 288.1 |
Income from operations | 36.8 | 32.4 |
Net interest expense | 3.9 | 3.8 |
Income before income tax provision | 32.9 | 28.6 |
Income tax provision | 7.1 | 10.4 |
Net income | $ 25.8 | $ 18.2 |
Net income (loss) per common share: | ||
Basic (in dollars per share) | $ (2.37) | $ 0.06 |
Diluted (in dollars per share) | $ (2.37) | $ 0.05 |
Weighted average shares used in calculating net income (loss) per common share: | ||
Basic (in shares) | 239,290,145 | 114,441,043 |
Diluted (in shares) | 239,290,145 | 169,620,178 |
Consolidated statements of comprehensive income | ||
Net income | $ 25.8 | $ 18.2 |
Other comprehensive income (loss): | ||
Net change on derivatives designated as cash flow hedges, net of tax | 0.5 | (4.4) |
Foreign currency translation adjustments | (0.4) | (2.1) |
Comprehensive income | 25.9 | 11.7 |
Basic: | ||
Net income | 25.8 | 18.2 |
Less dividends on preferred shares | (592.3) | (5.4) |
Less income allocated to preferred shareholders | 0 | (6.2) |
Net income (loss) available/allocated to common shareholders - basic | (566.5) | 6.6 |
Diluted: | ||
Net income | 25.8 | 18.2 |
Less dividends on preferred shares | (592.3) | (5.4) |
Less income allocated to preferred shareholders | 0 | (5) |
Net income (loss) available/allocated to common shareholders - diluted | $ (566.5) | $ 7.8 |
Consolidated Statements of Op_2
Consolidated Statements of Operations and Comprehensive Income (Unaudited) (Parenthetical) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Income Statement [Abstract] | ||
Revenue from related parties | $ 215.5 | $ 208.4 |
Consolidated Statements of Stoc
Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Millions | Total | Cumulative Effect, Period of Adoption, Adjustment | Cumulative Effect, Period of Adoption, Adjusted Balance | Common Stock | Common StockCumulative Effect, Period of Adoption, Adjusted Balance | Treasury Stock | Treasury StockCumulative Effect, Period of Adoption, Adjusted Balance | Additional Paid-In Capital | Additional Paid-In CapitalCumulative Effect, Period of Adoption, Adjusted Balance | Accumulated Deficit | Accumulated DeficitCumulative Effect, Period of Adoption, Adjustment | Accumulated DeficitCumulative Effect, Period of Adoption, Adjusted Balance | Accumulated Other Comprehensive Loss | Accumulated Other Comprehensive LossCumulative Effect, Period of Adoption, Adjusted Balance |
Beginning Balance (in shares) at Dec. 31, 2019 | 127,807,546 | 127,807,546 | 13,786,266 | 13,786,266 | ||||||||||
Beginning Balance at Dec. 31, 2019 | $ 18.1 | $ (0.8) | $ 17.3 | $ 1.3 | $ 1.3 | $ (73.6) | $ (73.6) | $ 372.7 | $ 372.7 | $ (277.8) | $ (0.8) | $ (278.6) | $ (4.5) | $ (4.5) |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||||||||||
Accounting Standards Update [Extensible List] | us-gaap:AccountingStandardsUpdate201613Member | |||||||||||||
Share-based compensation expense | $ 4.8 | 4.8 | ||||||||||||
Issuance of common stock related to share-based compensation plans (in shares) | 1,720 | |||||||||||||
Exercise of vested stock options (in shares) | 553,520 | |||||||||||||
Exercise of vested stock options | 3.1 | 3.1 | ||||||||||||
Dividends paid/accrued | (5.4) | (5.4) | ||||||||||||
Acquisition of treasury stock related to share-based compensation plans (in shares) | (545) | |||||||||||||
Net change on derivatives designated as cash flow hedges, net of tax | (4.4) | (4.4) | ||||||||||||
Foreign currency translation adjustments | (2.1) | (2.1) | ||||||||||||
Net income | 18.2 | 18.2 | ||||||||||||
Ending Balance (in shares) at Mar. 31, 2020 | 128,362,786 | 13,786,811 | ||||||||||||
Ending Balance at Mar. 31, 2020 | 31.5 | $ 1.3 | $ (73.6) | 375.2 | (260.4) | (11) | ||||||||
Beginning Balance (in shares) at Dec. 31, 2020 | 137,812,559 | 16,668,521 | ||||||||||||
Beginning Balance at Dec. 31, 2020 | $ 87.9 | $ 1.4 | $ (139.2) | 393.7 | (161.5) | (6.5) | ||||||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||||||||||
Accounting Standards Update [Extensible List] | us-gaap:AccountingStandardsUpdate201613Member | |||||||||||||
Share-based compensation expense | $ 12.8 | 12.8 | ||||||||||||
Issuance of common stock related to share-based compensation plans (in shares) | 6,497 | |||||||||||||
Issuance of common stock (in shares) | 324,212 | |||||||||||||
Issuance of common stock | $ 7 | 7 | ||||||||||||
Exercise of vested stock options (in shares) | 539,795 | 539,795 | ||||||||||||
Exercise of vested stock options | $ 3.5 | 3.5 | ||||||||||||
Acquisition of treasury stock related to share-based compensation plans (in shares) | (2,201) | |||||||||||||
Net change on derivatives designated as cash flow hedges, net of tax | 0.5 | 0.5 | ||||||||||||
Foreign currency translation adjustments | (0.4) | (0.4) | ||||||||||||
Conversion of preferred shares (in shares) | 117,706,400 | |||||||||||||
Conversion of preferred shares | 251.5 | $ 1.2 | 250.3 | |||||||||||
Inducement dividend | (592.3) | (592.3) | ||||||||||||
Issuance of common stock related to inducement (in shares) | 21,582,800 | |||||||||||||
Issuance of common stock related to inducement | 487.3 | $ 0.2 | 487.1 | |||||||||||
Net income | 25.8 | 25.8 | ||||||||||||
Ending Balance (in shares) at Mar. 31, 2021 | 277,972,263 | 16,670,722 | ||||||||||||
Ending Balance at Mar. 31, 2021 | $ 283.6 | $ 2.8 | $ (139.2) | $ 562.1 | $ (135.7) | $ (6.4) |
Consolidated Statements of St_2
Consolidated Statements of Stockholders' Equity (Unaudited) (Parenthetical) - USD ($) $ in Millions | 3 Months Ended | 12 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | Dec. 31, 2019 | |
Accumulated Other Comprehensive Loss | |||
Net change on derivatives designated as cash flow hedges, tax | $ 0.2 | $ 1.5 | |
Cumulative Effect, Period of Adoption, Adjustment | |||
Impact of credit-loss standard adoption, tax | $ 0.3 |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Operating activities | ||
Net income | $ 25.8 | $ 18.2 |
Adjustments to reconcile net income to net cash provided by operations: | ||
Depreciation and amortization | 17.9 | 15.7 |
Amortization of debt issuance costs | 0.3 | 0.2 |
Share-based compensation | 12.7 | 4.8 |
Loss on disposal and right-of-use asset write-downs | 0.6 | 0 |
Provision for credit losses | 0.1 | 0.8 |
Deferred income taxes | 4.9 | 8.9 |
Non-cash lease expense | 2.9 | 2.9 |
Change in value of contingent consideration | 0.5 | 0 |
Changes in operating assets and liabilities: | ||
Accounts receivable and related party accounts receivable | (7.3) | (12.5) |
Prepaid expenses and other assets | (19.4) | (5.2) |
Accounts payable | 5.2 | 2.8 |
Accrued compensation and benefits | 9.4 | (46.6) |
Lease liabilities | (4.1) | (2.6) |
Other liabilities | (4.2) | 16 |
Customer liabilities and customer liabilities - related party | 0.7 | (2.8) |
Net cash provided by operating activities | 46 | 0.6 |
Investing activities | ||
Purchases of property, equipment, and software | (9.6) | (13.3) |
Net cash used in investing activities | (9.6) | (13.3) |
Financing activities | ||
Repayment of senior secured debt and revolver | (6.5) | (4.1) |
Inducement of preferred stock conversion | (105) | 0 |
Exercise of vested stock options | 4.4 | 3.1 |
Finance lease payments | 0 | (0.6) |
Net cash (used in) provided by financing activities | (107.1) | 28.4 |
Effect of exchange rate changes in cash, cash equivalents and restricted cash | (0.1) | (1.2) |
Net (decrease) increase in cash, cash equivalents and restricted cash | (70.8) | 14.5 |
Cash, cash equivalents and restricted cash, at beginning of period | 174.8 | 92.5 |
Cash, cash equivalents and restricted cash, at end of period | 104 | 107 |
Supplemental disclosures of cash flow information | ||
Accrued dividends payable to preferred stockholders | 0 | 5.4 |
Accrued and other liabilities related to purchases of property, equipment and software | 7.9 | 18.4 |
Accounts payable related to purchases of property, equipment and software | 2.4 | 3.1 |
Interest paid | 3.8 | 3.2 |
Income taxes paid | 0.6 | 0.9 |
Senior Revolver | ||
Financing activities | ||
Borrowings on revolver | 0 | 50 |
Repayment of senior secured debt and revolver | $ 0 | $ (20) |
Business Description and Basis
Business Description and Basis of Presentation | 3 Months Ended |
Mar. 31, 2021 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Business Description and Basis of Presentation | Business Description and Basis of Presentation Business Description R1 RCM Inc. (the “Company”) is a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers. The Company helps healthcare providers generate sustainable improvements in their operating margins and cash flows while also enhancing patient, physician, and staff satisfaction for its customers. For further information regarding the Company's business, including relationships with Ascension Health (“Ascension”) and TowerBrook Capital Partners (“TowerBrook”), refer to Note 1 of the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2020 (the “2020 Form 10-K”). SCI Solutions, Inc. Acquisition On April 1, 2020, the Company completed the acquisition of scheduling.com, Inc. d/b/a SCI Solutions, Inc. (“SCI”) pursuant to a stock purchase agreement dated as of January 9, 2020 (the “Stock Purchase Agreement”), by and among the Company, Clearsight Intermediate Holdings, Inc. (“Clearsight Holdings”) and Clearsight Group Holdings, LLC (the “Seller”) (the “SCI Acquisition”). At the closing of the transaction, the Company purchased from the Seller all of the issued and outstanding equity interests of Clearsight Holdings, which owns all of the issued and outstanding equity interests of SCI. SCI is a leading provider of software-as-a-service (“SaaS”)-based scheduling and patient access solutions. SCI’s platform streamlines the patient and provider experience, creating efficient care networks where health systems’ capacity is digitally and conveniently accessible to all market constituents. The combination of R1 and SCI is expected to deliver enhanced value for healthcare providers by enabling them to expand digital front door strategies for their patients, improve operating efficiency, and increase capacity utilization, among other benefits. Refer to Note 4, Acquisitions for additional details. RevWorks Acquisition On August 3, 2020, the Company completed the acquisition of the RevWorks services business pursuant to an asset purchase agreement dated as of June 2, 2020 (the “RevWorks Purchase Agreement”) by and among the Company and Cerner Corporation (the “RevWorks Acquisition”). At the closing of the transaction, the Company purchased certain assets relating to the RevWorks services business, as specified in the RevWorks Purchase Agreement. The combination of R1 and RevWorks is expected to provide enhanced revenue cycle capabilities and expertise to RevWorks clients, helping drive sustainable financial improvements for providers while improving their patients’ overall experience. Refer to Note 4, Acquisitions for additional details. Emergency Medical Services Disposition As part of the Company’s portfolio analysis and strategic initiatives, the Company disposed the emergency medical services (“EMS”) business on October 30, 2020 for $140.0 million, inclusive of a $5.0 million hold-back amount subject to the completion of certain transition services, to be paid approximately one year from the date of the disposition (the “EMS Disposition”). The total sale price net of costs to sale was $132.7 million, which included customary adjustments for working capital, indebtedness, cash, and transaction expenses. R1 allocated goodwill to the disposed business based on the relative fair value methodology. The total goodwill allocated to the EMS Disposition was $7.1 million. The gain recognized on the EMS Disposition was $55.7 million. Basis of Presentation The accompanying unaudited consolidated financial statements reflect the Company's financial position as of March 31, 2021, the results of operations of the Company for the three months ended March 31, 2021 and 2020, and the cash flows of the Company for the three months ended March 31, 2021 and 2020. These financial statements include the accounts of R1 RCM Inc. and its wholly-owned subsidiaries. All material intercompany amounts have been eliminated in consolidation. These financial statements have been prepared in accordance with United States generally accepted accounting principles (“GAAP”) for interim financial reporting and as required by the rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”). Accordingly, certain information and footnote disclosures required for complete financial statements are not included herein. In the opinion of management, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the interim financial information, have been included. Operating results for the three months ended March 31, 2021 are not necessarily indicative of the results that may be expected for any other interim period or for the fiscal year ending December 31, 2021. |
Recent Accounting Pronouncement
Recent Accounting Pronouncements | 3 Months Ended |
Mar. 31, 2021 | |
Accounting Policies [Abstract] | |
Recent Accounting Pronouncements | Recent Accounting Pronouncements Recently Issued Accounting Standards and Disclosures No new accounting pronouncements issued or effective during the fiscal year had, or is expected to have, a material impact on the Company’s consolidated financial statements. |
Fair Value of Financial Instrum
Fair Value of Financial Instruments | 3 Months Ended |
Mar. 31, 2021 | |
Fair Value Disclosures [Abstract] | |
Fair Value of Financial Instruments | Fair Value of Financial Instruments The Company's accounting policy for fair values, including details of the fair value hierarchy levels, are outlined in Note 4 of the Company's 2020 Form 10-K. The carrying amounts of the Company’s financial instruments, which include financial assets such as cash and cash equivalents, restricted cash equivalents, accounts receivable, net, and certain other current assets, as well as financial liabilities such as accounts payable, accrued service costs, accrued compensation and benefits, and certain other accrued expenses, approximate their fair values, due to the short-term nature of these instruments. See Note 21, Derivative Financial Instruments, for a discussion of the fair value of the Company's forward currency derivative contracts and interest rate swaps. |
Acquisitions
Acquisitions | 3 Months Ended |
Mar. 31, 2021 | |
Business Combinations [Abstract] | |
Acquisitions | Acquisitions SCI On April 1, 2020, the Company completed the acquisition of SCI. The SCI Acquisition has been accounted for under ASC 805, Business Combinations. Accordingly, the accounts of the acquired company, after adjustments to reflect fair values assigned to assets and liabilities, have been included in the Company’s consolidated financial statements since the date of the SCI Acquisition. The purchase price for the SCI Acquisition was $190.0 million, subject to customary adjustments for cash, transaction expenses, earn-out consideration, and normalized working capital. The Company funded the purchase price for the SCI Acquisition and the Company’s associated transaction expenses with a combination of cash on hand and the incurrence of additional indebtedness (see Note 11, Debt). The fair value of assets acquired and liabilities assumed is (in millions): Purchase Price Allocation Total purchase consideration $ 197.0 Allocation of consideration to assets acquired and liabilities assumed: Cash and cash equivalents $ 2.9 Accounts receivable 2.8 Prepaid expenses and other current assets 1.2 Property, equipment and software 0.3 Operating lease right-of-use assets 1.2 Intangible assets 86.1 Goodwill 125.8 Accounts payable (0.2) Current portion of customer liabilities (4.0) Accrued compensation and benefits (1.6) Current portion of operating lease liabilities (0.5) Other accrued expenses (0.4) Non-current portion of operating lease liabilities (0.7) Other non-current liabilities (5.0) Deferred income tax liabilities (10.9) Net assets acquired $ 197.0 Other non-current liabilities contained a note payable for $5.0 million. The Company repaid this note in the second quarter of 2020. The goodwill recognized is primarily attributable to synergies that are expected to be achieved from the integration of SCI. None of the goodwill is expected to be deductible for income tax purposes. The purchase price includes an earn-out provision, which is dependent on achieving certain revenue and operational targets in the year following the acquisition. Based on projections at the time of acquisition, the earn-out was valued at $4.8 million. As of March 31, 2021, the Company determined the performance metrics for the earn-out had been met, and expects to pay the full earn-out of $10.0 million in the second quarter of 2021. Changes to the earn-out value were recorded as a component of other expenses. RevWorks On August 3, 2020, the Company completed the acquisition of RevWorks. The RevWorks Acquisition has been accounted for under ASC 805, Business Combinations. Accordingly, the accounts of the acquired company, after adjustments to reflect estimated fair values assigned to assets and liabilities, have been included in the Company’s consolidated financial statements since the date of the RevWorks Acquisition. The $30.0 million purchase consideration for the RevWorks Acquisition (inclusive of working capital) consisted of a $5.0 million payment at closing and two deferred payments, each of $12.5 million and totaling $25.0 million, which are due and payable on the first and second anniversary of the closing date. The two deferred payments are contractual obligations of the Company; however, they are potentially effectively refundable to the Company contingent on the achievement of certain pre-existing customer revenue targets for the RevWorks business that were agreed in the purchase agreement. If such targets are not achieved, this will result in Cerner Corporation (“Cerner”) returning to the Company up to $25.0 million. At the time of the acquisition, the Company recorded a present value liability for the contractual deferred payments of $24.3 million, and recorded an asset for the contingently returnable consideration of $22.3 million, including $11.5 million in prepaid expenses and $10.8 million in other assets on the Consolidated Balance Sheets, which is measured at fair value. The Company reviewed the balances at March 31, 2021 and determined that the fair value remained the same. The assets acquired in the RevWorks Acquisition consist primarily of customer relationships of approximately $2.8 million and fixed assets. There were no significant pre-closing liabilities of the RevWorks business included in the RevWorks Acquisition. The fair value estimate of assets acquired and liabilities assumed are pending completion of multiple elements, including gathering further information about the identification and completeness of all assets and liabilities acquired. The goodwill recognized of approximately $3.6 million is primarily attributable to synergies that are expected to be achieved from the integration of RevWorks. Pro Forma Results The following table summarizes, on a pro forma basis, the combined results of the Company as though the SCI and RevWorks acquisitions had occurred as of January 1, 2019. These pro forma results are not necessarily indicative of either the actual consolidated results had the acquisitions occurred as of January 1, 2019 or of the future consolidated operating results for any period. Pro forma results are (in millions): Three Months Ended March 31, 2020 Net services revenue $ 349.6 Net income $ 17.3 Adjustments were made to earnings to adjust depreciation and amortization to reflect fair value of identified assets acquired, to record the effects of extinguishing the debt of SCI and replacing it with the debt of the Company, and to record the income tax effect of these adjustments. |
Accounts Receivable and Allowan
Accounts Receivable and Allowance for Credit Losses | 3 Months Ended |
Mar. 31, 2021 | |
Receivables [Abstract] | |
Accounts Receivable and Allowance for Credit Losses | Accounts Receivable and Allowance for Credit Losses Accounts receivable is comprised of unpaid balances pertaining to modular services and end-to-end revenue cycle management (“RCM”) customers, net receivable balances for end-to-end RCM customers after considering cost reimbursements owed to such customers, including related accrued balances, and amounts due from physician RCM and practice management customers. The Company evaluates its accounts receivable for expected credit losses quarterly. The Company maintains an estimated allowance for credit losses to reduce its accounts receivable to the amount that it believes will be collected. This allowance is based on the Company’s historical experience, its assessment of each customer’s ability to pay, the length of time a balance has been outstanding, input from key Company resources assigned to each customer, the status of any ongoing operations with each applicable customer, and environmental factors such as significant shifts in the healthcare environment which the Company believes may have impacted or will impact its customers’ financial health and ability to pay. The full effects of COVID-19 on the Company’s customers are uncertain and cannot be predicted. As a result, the Company’s future collection experience may differ from historical collection trends. The Company has presented the rollforward below on a consolidated basis as the currently expected credit losses for its large integrated healthcare system customers are not anticipated to be material. Movements in the allowance for credit losses are as follows (in millions): Three Months Ended March 31, 2021 2020 Beginning balance $ 3.8 $ 2.8 Cumulative effect of ASC 326 — 1.1 Provision (recoveries) 0.1 0.8 Ending balance $ 3.9 $ 4.7 |
Property, Equipment and Softwar
Property, Equipment and Software | 3 Months Ended |
Mar. 31, 2021 | |
Property, Plant and Equipment [Abstract] | |
Property, Equipment and Software | Property, Equipment and Software Property, equipment and software consist of the following (in millions): March 31, 2021 December 31, 2020 Buildings and land $ 4.6 $ 4.6 Computer and other equipment 56.6 55.0 Leasehold improvements 23.3 23.2 Software 142.3 135.7 Office furniture 6.4 6.4 Property, equipment and software, gross 233.2 224.9 Less accumulated depreciation and amortization (144.2) (131.2) Property, equipment and software, net $ 89.0 $ 93.7 The following table summarizes the allocation of depreciation and amortization expense between cost of services and selling, general and administrative expenses (in millions): Three Months Ended March 31, 2021 2020 Cost of services $ 12.7 $ 10.9 Selling, general and administrative 0.8 1.3 Total depreciation and amortization $ 13.5 $ 12.2 |
Leases
Leases | 3 Months Ended |
Mar. 31, 2021 | |
Leases [Abstract] | |
Leases | Leases The Company's accounting policy for leases, including the elections made as part of the adoption of ASC 842 effective January 1, 2019, are outlined in Note 8 of the Company's 2020 Form 10-K. The components of lease costs are as follows (in millions): Three Months Ended March 31, 2021 2020 Operating lease cost $ 4.1 $ 4.9 Finance lease cost: Amortization of right-of-use (“ROU”) assets 0.1 0.2 Interest on lease liabilities — 0.1 Sublease income (0.6) (0.6) Total lease cost $ 3.6 $ 4.6 Supplemental cash flow information related to leases are as follows (in millions): Three Months Ended March 31, 2021 2020 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows for operating leases $ 9.4 $ 4.9 Operating cash flows for finance leases — 0.1 Financing cash flows for finance leases — 0.6 ROU assets obtained in exchange for lease obligations: Operating leases 5.6 1.7 The Company presents all non-cash transactions related to adjustments to the lease liability or ROU asset as non-cash transactions. This includes all non-cash charges related to any modification or reassessment events triggering remeasurement, and obtaining new leases for non-cash consideration. Supplemental balance sheet information related to leases are as follows: March 31, 2021 December 31, 2020 Weighted average remaining lease term: Operating leases 7 years 7 years Finance leases 3 years 2 years Weighted average incremental borrowing rate: Operating leases 8.99 % 8.94 % Finance leases 6.71 % 6.62 % Maturities of lease liabilities as of March 31, 2021 are as follows (in millions): Operating Leases Finance Leases Remainder of 2021 $ 14.0 $ 0.1 2022 16.0 0.1 2023 15.2 — 2024 15.3 — 2025 15.2 — 2026 12.0 — Thereafter 22.1 — Total 109.8 0.2 Less: Imputed interest 29.3 — Present value of lease liabilities $ 80.5 $ 0.2 |
Leases | Leases The Company's accounting policy for leases, including the elections made as part of the adoption of ASC 842 effective January 1, 2019, are outlined in Note 8 of the Company's 2020 Form 10-K. The components of lease costs are as follows (in millions): Three Months Ended March 31, 2021 2020 Operating lease cost $ 4.1 $ 4.9 Finance lease cost: Amortization of right-of-use (“ROU”) assets 0.1 0.2 Interest on lease liabilities — 0.1 Sublease income (0.6) (0.6) Total lease cost $ 3.6 $ 4.6 Supplemental cash flow information related to leases are as follows (in millions): Three Months Ended March 31, 2021 2020 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows for operating leases $ 9.4 $ 4.9 Operating cash flows for finance leases — 0.1 Financing cash flows for finance leases — 0.6 ROU assets obtained in exchange for lease obligations: Operating leases 5.6 1.7 The Company presents all non-cash transactions related to adjustments to the lease liability or ROU asset as non-cash transactions. This includes all non-cash charges related to any modification or reassessment events triggering remeasurement, and obtaining new leases for non-cash consideration. Supplemental balance sheet information related to leases are as follows: March 31, 2021 December 31, 2020 Weighted average remaining lease term: Operating leases 7 years 7 years Finance leases 3 years 2 years Weighted average incremental borrowing rate: Operating leases 8.99 % 8.94 % Finance leases 6.71 % 6.62 % Maturities of lease liabilities as of March 31, 2021 are as follows (in millions): Operating Leases Finance Leases Remainder of 2021 $ 14.0 $ 0.1 2022 16.0 0.1 2023 15.2 — 2024 15.3 — 2025 15.2 — 2026 12.0 — Thereafter 22.1 — Total 109.8 0.2 Less: Imputed interest 29.3 — Present value of lease liabilities $ 80.5 $ 0.2 |
Intangible Assets
Intangible Assets | 3 Months Ended |
Mar. 31, 2021 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Intangible Assets | Intangible Assets The following table provides the gross carrying value and accumulated amortization for each major class of intangible asset at March 31, 2021 and December 31, 2020 (in millions): March 31, 2021 December 31, 2020 Gross Carrying Value Accumulated Amortization Net Book Value Gross Carrying Value Accumulated Amortization Net Book Value Customer relationships $ 97.7 $ (16.2) $ 81.5 $ 97.7 $ (14.7) $ 83.0 Technology 101.7 (16.5) 85.2 101.7 (13.6) 88.1 Total intangible assets $ 199.4 $ (32.7) $ 166.7 $ 199.4 $ (28.3) $ 171.1 Intangible asset amortization expense was $4.4 million and $3.5 million for the three months ended March 31, 2021 and 2020, respectively. Estimated annual amortization expense related to intangible assets with definite lives as of March 31, 2021 is as follows (in millions): Remainder of 2021 $ 12.9 2022 17.3 2023 17.3 2024 15.5 2025 14.5 2026 14.5 Thereafter 74.7 Total $ 166.7 |
Goodwill
Goodwill | 3 Months Ended |
Mar. 31, 2021 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Goodwill | GoodwillUnless otherwise required, goodwill is tested for impairment annually in the fourth quarter. Changes in the carrying amount of goodwill for the three months ended March 31, 2021 were (in millions): Goodwill Balance as of December 31, 2020 $ 375.3 Measurement period adjustments 0.2 Balance as of March 31, 2021 $ 375.5 |
Revenue Recognition
Revenue Recognition | 3 Months Ended |
Mar. 31, 2021 | |
Revenue from Contract with Customer [Abstract] | |
Revenue Recognition | Revenue Recognition The Company follows the guidance under Topic 606, Revenue from Contracts with Customers (“Topic 606”). Revenue is measured based on consideration specified in a contract with a customer, and excludes any sales incentives and amounts collected on behalf of third parties. The Company recognizes revenue when it satisfies a performance obligation by transferring control over a service to a customer, which is typically over the contact term. Estimates of variable consideration are included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur once the uncertainty is resolved. Disaggregation of Revenue In the following table, revenue is disaggregated by source (in millions): Three Months Ended March 31, 2021 2020 Net operating fees $ 286.1 $ 280.9 Incentive fees 29.0 16.8 Other 27.5 22.8 Net services revenue $ 342.6 $ 320.5 Contract Balances The following table provides information about receivables, contract assets, and contract liabilities from contracts with customers (in millions): March 31, 2021 December 31, 2020 Receivables (1) $ 129.4 $ 122.2 Contract assets (2) 6.7 — Contract liabilities (2) 25.7 28.6 (1) Receivables are included in accounts receivable, net. The balance includes accounts receivable, net - related party. (2) Contract assets and contract liabilities are included in other current assets and customer liabilities, respectively. The contract liabilities balance contains related party amounts, including $3.9 million and $5.6 million of current customer liabilities and $15.4 million and $16.3 million of non-current customer liabilities for the three months ended March 31, 2021 and year ended December 31, 2020, respectively. A receivable is recognized in the period the Company provides services when the Company’s right to consideration is unconditional. Payment terms on invoiced amounts are typically 30-60 days. The Company recognized revenue of $93.7 million and $86.0 million during the three months ended March 31, 2021 and 2020, which amounts were included in contract liabilities at the beginning of the respective periods. These revenue amounts include $88.1 million and $85.0 million for the three months ended March 31, 2021 and 2020, respectively, related to advanced billings which become accounts receivable and contract liabilities on the first day of the respective service period. Transaction Price Allocated to the Remaining Performance Obligation The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period (in millions). The estimated revenue does not include amounts of variable consideration that are constrained. Net operating fees Incentive fees Other Remainder of 2021 $ 83.9 $ 31.4 $ 1.7 2022 70.0 — — 2023 55.0 — — 2024 35.0 — — 2025 11.7 — — 2026 5.6 — — Thereafter — — — Total $ 261.2 $ 31.4 $ 1.7 The amounts presented in the table above include variable fee estimates for the non-cancellable term of the Company's physician groups RCM services contracts, fixed fees which are typically recognized ratably as the performance obligation is satisfied, and incentive fees which are measured cumulatively over the contractually defined performance period. Certain costs associated with the initial phases of customer contracts and the related transition of customer hospitals and physician groups are deferred. These fulfillment costs relate directly to the Company’s responsibilities under the corresponding customer contracts, generate or enhance resources of the Company that will be used in satisfying its performance obligations in the future, and are expected to be recovered through the margins realized. The following table summarizes the breakout of deferred contract costs (in millions): March 31, 2021 December 31, 2020 Prepaid expenses and other current assets $ 4.7 $ 4.5 Other assets 19.5 19.6 Total deferred contract costs $ 24.2 $ 24.1 The associated assets are amortized as services are transferred to the customer over the remaining life of the contracts. For the three months ended March 31, 2021 and 2020, total amortization was $1.2 million and $1.1 million, respectively, and there were no associated impairment losses. |
Debt
Debt | 3 Months Ended |
Mar. 31, 2021 | |
Debt Disclosure [Abstract] | |
Debt | Debt The carrying amounts of debt consist of the following (in millions): March 31, 2021 December 31, 2020 Senior Revolver $ 70.0 $ 70.0 Senior Term Loan 478.1 484.6 Unamortized discount and issuance costs (2.4) (2.6) Total debt 545.7 552.0 Less: Current maturities (35.5) (32.3) Total long-term debt $ 510.2 $ 519.7 Senior Secured Credit Facilities On June 26, 2019, the Company and certain of its subsidiaries entered into a senior credit agreement (the “Credit Agreement”) with Bank of America, N.A., as administrative agent, and the lenders named therein, for senior secured credit facilities (the “Senior Secured Credit Facilities”), consisting of a $325.0 million senior secured term loan facility (the “Senior Term Loan”) issued at 99.66% of par and a $100.0 million senior secured revolving credit facility (the “Senior Revolver”). On March 20, 2020, the Company entered into Amendment No. 1 to the Credit Agreement (the “Amendment”), pursuant to which the lenders named in the Amendment agreed to provide an additional $191.1 million incremental delayed-draw term loan facility (the “Incremental Term Loan”) on the same terms as its existing Senior Term Loan provided under the Credit Agreement. The Incremental Term Loan was drawn substantially concurrently with the closing of the SCI Acquisition on April 1, 2020. The proceeds of the Incremental Term Loan were used to fund the purchase price for the SCI Acquisition and related expenses. For further details on the closing, refer to Note 4, Acquisitions. The Incremental Term Loan has terms consistent with those of the Senior Term Loan, including with respect to interest, maturity, amortization, and prepayments and has the same affirmative and negative covenants and events of default as those applicable to the Senior Term Loan under the Credit Agreement. The drawing of the Incremental Term Loan increased the balance of the obligation due under the Senior Term Loan, and therefore is shown as one consolidated obligation. In accordance with ASC 470-50, the Amendment was treated as a loan modification in the financial statements. On January 13, 2021, the Company entered into Amendment No. 2 and Waiver to Credit Agreement (the “Second Amendment”), pursuant to which the lenders agreed (i) to waive the Company’s obligation to use the $135.0 million of net proceeds from the EMS Disposition for purposes of reinvestments in useful assets of the Company, or to prepay the loans under the Credit Agreement, as otherwise required by the terms of the Credit Agreement, (ii) to amend the restricted payments covenant to permit the Company to make additional cash payments to the Investor in an amount not to exceed $105.0 million in connection with the preferred stock conversion (refer to Note 15. 8.00% Series A Convertible Preferred Stock) and reduce the “Available Amount” from which the Company can make certain investments, debt prepayments, or restricted payments by $105.0 million and (iii) that the excess cash flow sweep will begin with fiscal year ended December 31, 2021 instead of fiscal year ended December 31, 2020. The Senior Revolver includes borrowing capacity available for letters of credit and for borrowings on same-day notice, referred to as the “swing loans.” Any issuance of letters of credit or making of a swing loan will reduce the amount available under the revolving credit facility. As of March 31, 2021, the Company had $70.0 million in borrowings, no letters of credit outstanding, and $30.0 million of availability under the Senior Revolver. Borrowings under the Senior Secured Credit Facilities bear interest, at the Company’s option, at: (i) an Alternate Base Rate (“ABR”) equal to the greater of (a) the prime rate of Bank of America, N.A., (b) the federal funds rate plus 0.50% per annum , and (c) the Eurodollar rate for an interest period of one-month beginning on such day plus 100 basis points, plus between 0.75% and 1.75% dependent on the Company's Net Leverage Ratio (provided that the Eurodollar rate applicable to the Term Loan Facility shall not be less than 0.00% per annum); or (ii) the Eurodollar rate (provided that the Eurodollar rate applicable to the Term Loan Facility shall not be less than 0.00% per annum), plus between 1.75% and 2.75%, dependent on the Company's Net Leverage Ratio. The interest rate as of March 31, 2021 was 2.36%. The Company is also required to pay an unused commitment fee to the lenders under the Senior Revolver at a rate between 0.30% and 0.50% of the average daily unutilized commitments thereunder dependent on the Company's net leverage ratio. The Credit Agreement contains a number of covenants that, among other things, restrict, subject to certain exceptions, the Company’s ability and the ability of its subsidiaries to: (i) incur additional indebtedness; (ii) create liens on assets; (iii) engage in mergers or consolidations; (iv) sell assets; (v) pay dividends and distributions or repurchase the Company’s capital stock; (vi) make investments, loans or advances; (vii) repay certain junior indebtedness; (viii) engage in certain transactions with affiliates; (ix) enter into sale and leaseback transactions; (x) amend material agreements governing certain of the Company’s junior indebtedness; (xi) change the Company’s lines of business; (xii) make certain acquisitions; and (xiii) limitations on the letter of credit cash collateral account. The Credit Agreement contains customary affirmative covenants and events of default. In addition, the Company is required to maintain minimum consolidated total net leverage and consolidated interest coverage ratios. The Company was in compliance with all of the covenants in the Credit Agreement as of March 31, 2021. Debt Maturities Scheduled maturities of the Company’s long-term debt are summarized as follows (in millions): Scheduled Maturities Remainder of 2021 $ 25.8 2022 38.7 2023 45.2 2024 438.4 Total $ 548.1 For further details on the Company's debt, refer to Note 13 of the Company's 2020 Form 10-K. |
Share-Based Compensation
Share-Based Compensation | 3 Months Ended |
Mar. 31, 2021 | |
Share-based Payment Arrangement [Abstract] | |
Share-Based Compensation | Share-Based Compensation The share-based compensation expense relating to the Company’s stock options, restricted stock units (“RSUs”), and performance-based restricted stock units (“PBRSUs”) for the three months ended March 31, 2021 and 2020 was $12.7 million and $4.8 million, respectively, with related tax benefits of approximately $2.2 million and $0.7 million, respectively. The Company accounts for forfeitures as they occur. Excess tax benefits and shortfalls for share-based payments are recognized in income tax expense (benefit) and included in operating activities. The Company recognized $2.3 million and $0.6 million of income tax benefit from windfalls associated with vesting and exercises of equity awards for the three months ended March 31, 2021 and 2020, respectively. Total share-based compensation costs that have been included in the Company’s consolidated statements of operations were as follows (in millions): Three Months Ended March 31, 2021 2020 Share-Based Compensation Expense Allocation Details: Cost of services $ 7.3 $ 1.9 Selling, general and administrative 5.4 2.9 Other — — Total share-based compensation expense $ 12.7 $ 4.8 The Company uses the Black-Scholes option pricing model to estimate the fair value of its service-based options as of their grant dates. Monte Carlo simulations are used to estimate the fair value of its market-based PBRSUs. The market-based PBRSUs vest upon satisfaction of both time-based requirements and market targets based on share price. Expected life is based on the market condition to which the vesting is tied. The Company assesses current performance on performance-based PBRSUs by reviewing historical performance to date, along with any adjustments which have been approved to the reported performance, and changes to the projections to determine the probable outcome of the awards. The current estimates are then compared to the scoring metrics and any necessary adjustments are reflected in the current period to update share-based compensation expense to the current performance expectations. The following table sets forth the significant assumptions used in the Black-Scholes option pricing model and the Monte Carlo simulations and the calculation of share-based compensation expense for the three months ended March 31, 2021 and 2020: Three Months Ended March 31, 2021 2020 Expected dividend yield —% —% Risk-free interest rate 0.4% 1.7% Expected volatility 43% 43% Expected term (in years) 5.5 5.5 The risk-free interest rate input is based on U.S. Treasury instruments, and the expected volatility of the share price is based on review of the historical volatility levels of the Company’s common stock in conjunction with that of public companies that operate in similar industries or are similar in terms of stage of development or size and a projection of this information toward its future expected volatility. The Company used the simplified method to estimate the expected option life. The simplified method was used due to the lack of sufficient historical data available to provide a reasonable basis upon which to estimate the expected term of each stock option. Stock options A summary of the options activity during the three months ended March 31, 2021 is shown below: Options Weighted- Outstanding at December 31, 2020 6,220,971 $ 3.68 Granted 1,625 23.49 Exercised (539,795) 6.47 Canceled/forfeited (1,040) 3.85 Expired — — Outstanding at March 31, 2021 5,681,761 $ 3.42 Outstanding, vested and exercisable at March 31, 2021 4,782,897 $ 3.41 Outstanding, vested and exercisable at December 31, 2020 5,230,690 $ 3.73 Restricted stock units and performance-based restricted stock units A summary of the RSU and PBRSU activity during the three months ended March 31, 2021 is shown below: Weighted- RSUs PBRSUs RSU PBRSU Outstanding and unvested at December 31, 2020 2,108,447 2,917,071 $ 9.87 $ 11.35 Granted 2,719 290,354 23.77 25.09 Vested (6,497) — 10.80 — Forfeited (41,381) (646) 12.99 5.34 Outstanding and unvested at March 31, 2021 2,063,288 3,206,779 $ 9.82 $ 12.59 Shares surrendered for taxes for the three months ended March 31, 2021 2,201 — Cost of shares surrendered for taxes for the three months ended March 31, 2021 (in millions) $ — $ — Shares surrendered for taxes for the three months ended March 31, 2020 545 — Cost of shares surrendered for taxes for the three months ended March 31, 2020 (in millions) $ — $ — Outstanding PBRSUs issued prior to April 2019 vest upon satisfaction of both time-based requirements and market targets based on share price. Depending on the percentage level at which the market-based condition is satisfied, the number of shares vesting could be between 0% and 150% of the number of PBRSUs originally granted. PBRSUs issued subsequent to April 2019 vest upon satisfaction of both time-based and performance-based conditions. Depending on the award, performance condition targets may include cumulative adjusted EBITDA, end-to-end RCM agreement growth, scored revenue growth, or other specific performance factors. Depending on the percentage level at which the performance-based conditions are satisfied, the number of shares vesting could be between 0% and 200% of the number of PBRSUs originally granted. Based on the established targets, the maximum number of shares that could vest for all outstanding PBRSUs is 5,943,470. |
Other Expenses
Other Expenses | 3 Months Ended |
Mar. 31, 2021 | |
Other Income and Expenses [Abstract] | |
Other Expenses | Other Expenses Other expenses consist of the following (in millions): Three Months Ended March 31, 2021 2020 Severance and related employee benefits $ 1.5 $ 1.1 Strategic initiatives (1) 6.5 3.2 Facility-exit charges (2) 1.5 0.4 Other (3) 3.5 4.0 Total other expenses $ 13.0 $ 8.7 (1) Costs related to evaluating, pursuing, and integrating acquisitions, performing portfolio and capital structure analyses and transactions, and other inorganic business projects as part of the Company’s growth strategy. Costs include vendor spend, employee time and expenses spent on activities, severance and retention amounts associated with integration activities, and changes to contingent consideration related to acquisitions. For the three months ended March 31, 2021, $0.5 million of contingent consideration changes were included. (2) As part of evaluating the Company’s footprint, R1 has exited certain leased facilities. Costs include asset impairment charges and other costs related to exited leased facilities. (3) For the three months ended March 31, 2021 and 2020, includes $1.7 million and $2.6 million, respectively, of expenses related to the COVID-19 pandemic, inclusive of appreciation bonuses for the Company’s front-line employees, pandemic response mobilization efforts, telemedicine and testing costs for employees, and other costs related to the COVID-19 pandemic. |
Income Taxes
Income Taxes | 3 Months Ended |
Mar. 31, 2021 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | Income Taxes Income tax provisions for interim periods are based on estimated annual income tax rates, adjusted to reflect the effects of any significant and infrequent or unusual items which are required to be discretely recognized within the current interim period. The effective tax rates in the periods presented are largely based upon the projected annual pre-tax earnings by jurisdiction and the allocation of certain expenses in various taxing jurisdictions where the Company conducts its business. These taxing jurisdictions apply a broad range of statutory income tax rates. The global intangible low-taxed income (“GILTI”) provisions impose taxes on foreign income in excess of a deemed return on tangible assets of foreign corporations. The Company elected to account for GILTI tax in the period in which it is incurred. The Company recognized income tax expense for the three months ended March 31, 2021 on the year-to-date pre-tax income. The deviation from the federal statutory tax rate of 21% is primarily attributable to recognizing the provisions for state taxes, GILTI, non-deductible compensation, and discrete items. The Company recognized income tax expense for the three months ended March 31, 2020 on the year-to-date pre-tax income. The deviation from the federal statutory tax rate of 21% is primarily attributable to recognizing the provisions for GILTI plus the geographical mix of earnings, permanent differences, and discrete items. The Company and its subsidiaries are subject to U.S. federal income tax as well as income tax of multiple state and foreign jurisdictions. U.S. federal income tax returns since 2017 are currently open for examination. State jurisdictions vary for open tax years. The statute of limitations for most states ranges from three At December 31, 2020, the Company had gross deferred tax assets of $146.1 million, of which $81.6 million related to net operating loss (“NOL”) carryforwards. The majority of the Company's carryforwards were generated in 2014 and 2016. The Company expects to be profitable, allowing the Company to utilize its NOL carryforward and other deferred tax assets. |
8.00% Series A Convertible Pref
8.00% Series A Convertible Preferred Stock | 3 Months Ended |
Mar. 31, 2021 | |
Temporary Equity Disclosure [Abstract] | |
8.00% Series A Convertible Preferred Stock | 8.00% Series A Convertible Preferred Stock On January 15, 2021, TCP-ASC ACHI Series LLLP (“TCP-ASC”), a limited liability limited partnership jointly owned by Ascension Health Alliance and investment funds affiliated with TowerBrook (the “Investor”), a related party, converted all of its 294,266 shares (the “Current Shares”) of preferred stock into 117,706,400 shares of common stock of the Company into which the Current Shares were convertible pursuant to the Certificate of Designation of the preferred stock, and, in consideration therefor, the Company (i) issued 21,582,800 additional shares of common stock to the Investor, and (ii) paid the Investor $105.0 million in cash. On January 19, 2021, the Company filed a Certificate of Elimination of 8.00% Series A Convertible Preferred Stock with the Secretary of State of the State of Delaware to eliminate the Certificate of Designations of the 8.00% Series A Convertible Preferred Stock. The consideration paid to induce the conversion was recorded as a dividend of $592.3 million and reduced income available to common shareholders in our earnings per share calculation. The dividend was calculated as the cash paid of $105.0 million plus the fair value on the conversion date of the additional 21,582,800 shares of common stock issued as consideration for the conversion. The following summarizes the preferred stock activity for the three months ended March 31, 2021 (in millions, except per share data): Preferred Stock Shares Issued and Outstanding Carrying Value Balance at December 31, 2020 288,497 $ 251.5 Dividends paid/accrued dividends 5,769 — Conversion of preferred stock (294,266) (251.5) Balance at March 31, 2021 — $ — |
Earnings (Loss) Per Share
Earnings (Loss) Per Share | 3 Months Ended |
Mar. 31, 2021 | |
Earnings Per Share [Abstract] | |
Earnings (Loss) Per Share | Earnings (Loss) Per Share Basic net income per share is computed by dividing net income, less any dividends, accretion or decretion, redemption or induced conversion on the preferred stock, by the weighted average number of common shares outstanding during the period. As the preferred stock participates in dividends alongside the Company’s common stock (per their participating dividends), the preferred stock would constitute participating securities under ASC 260-10 and are applied to earnings per share using the two-class method. Under this method, all earnings (distributed and undistributed) are allocated to common shares and participating securities based on their respective rights to receive dividends. Diluted net income per share is calculated using the more dilutive of the if-converted or the two-class method. For the three months ended March 31, 2021 and 2020, the two-class method was more dilutive and was computed by adjusting the denominator used in the basic net income per share computation by potentially dilutive securities outstanding during the period plus, when their effect is dilutive, incremental shares consisting of shares subject to stock options, shares issuable upon vesting of RSUs and PBRSUs, and shares issuable upon conversion of preferred stock. Basic and diluted net income (loss) per common share are calculated as follows (in millions, except share and per share data): Three Months Ended 2021 2020 Basic EPS: Net income $ 25.8 $ 18.2 Less dividends on preferred shares (1) (592.3) (5.4) Less income allocated to preferred shareholders — (6.2) Net income (loss) available/(allocated) to common shareholders - basic $ (566.5) $ 6.6 Diluted EPS: Net income $ 25.8 $ 18.2 Less dividends on preferred shares (1) (592.3) (5.4) Less income allocated to preferred shareholders — (5.0) Net income (loss) available/(allocated) to common shareholders - diluted $ (566.5) $ 7.8 Basic weighted-average common shares 239,290,145 114,441,043 Add: Effect of dilutive equity awards — 11,893,514 Add: Effect of dilutive warrants — 43,285,621 Diluted weighted average common shares 239,290,145 169,620,178 Net income (loss) per common share (basic) $ (2.37) $ 0.06 Net income (loss) per common share (diluted) $ (2.37) $ 0.05 (1) The 2021 dividend on preferred shares includes amounts related to the conversion of the preferred shares. See Note 15, 8.00% Series A Convertible Preferred Stock, to the consolidated financial statements included in this Quarterly Report on Form 10-Q for more information. Because of their anti-dilutive effect, 13,688,519 common share equivalents comprised of stock options, PBRSUs, and RSUs have been excluded from the diluted earnings per share calculation for the three months ended March 31, 2021. Additionally, for the three months ended March 31, 2021, the Investor's and Intermountain's exercisable warrants to acquire up to 60 million and 1.5 million shares, respectively, of the Company's common stock have been excluded from the diluted earnings per share calculation because they are anti-dilutive. For the three months ended March 31, 2021, the exercisable warrants equate to 53,206,631 dilutive shares under the treasury stock method. |
Commitments and Contingencies
Commitments and Contingencies | 3 Months Ended |
Mar. 31, 2021 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | Commitments and Contingencies Legal Proceedings Other than as described below, the Company is not presently a party to any material litigation or regulatory proceeding and is not aware of any pending or threatened litigation or regulatory proceeding against the Company which, individually or in the aggregate, could have a material adverse effect on its business, operating results, financial condition or cash flows. In May 2016, the Company was served with a False Claims Act case brought by a former emergency department service associate who worked at a hospital of one of the Company’s customers, MedStar Inc.’s Washington Hospital Center (“WHC”), along with WHC and three other hospitals that were PAS customers and a place holder, John Doe hospital, representing all PAS customers ( U.S. ex rel. Graziosi vs. Accretive Health, Inc. et. al.) , and seeking money damages, False Claims Act penalties, and plaintiff’s attorneys’ fees. The Third Amended Complaint alleges that the Company’s PAS business violates the federal False Claims Act. The case was originally filed under seal in 2013 in the federal district court in Chicago, was presented to the U.S. Attorney in Chicago, and the U.S. Attorney declined to intervene. The Company believes that it has meritorious defenses to all claims in the case and intends to vigorously defend itself against these claims. Both the Company’s and plaintiff’s motions for summary judgment were denied in December 2020, and the parties are presently conducting damages and expert discovery. Discovery and dispositive motions are expected to extend through January 2022, with trial, if necessary, in mid-to-late 2022. On April 13, 2021 and April 19, 2021, respectively, certain purported stockholders of the Company filed two complaints in the Delaware Court of Chancery regarding the Company’s January 15, 2021 recapitalization transaction with TCP-ASC, an investment vehicle owned jointly by Ascension and TowerBrook. Both complaints allege that TCP-ASC, Ascension, and TowerBrook controlled the Company and breached their fiduciary duties by using that alleged control to force the Company to overpay in redeeming TCP-ASC’s preferred stock as part of the recapitalization transaction. The plaintiffs seek an unspecified amount of damages against TCP-ASC, Ascension, and TowerBrook. The plaintiffs also allege that the Company and TCP-ASC entered into amendments to the Investor Rights Agreement that the plaintiffs contend contains provisions that are void under the Company’s charter, bylaws, and the Delaware General Corporation Law. The plaintiffs seek a declaratory judgment that these amendments are invalid, as well as attorneys’ fees and costs. The Company believes that it has meritorious defenses to all claims against the Company and intends to vigorously defend itself against these claims. |
Related Party Transactions
Related Party Transactions | 3 Months Ended |
Mar. 31, 2021 | |
Related Party Transactions [Abstract] | |
Related Party Transactions | Related Party Transactions This note encompasses transactions between Ascension and its affiliates, including AMITA Health, and the Company pursuant to the amended and restated Master Professional Services Agreement (“A&R MPSA”), including all supplements, amendments, and other documents entered into in connection therewith. For further details on the Company's agreements with Ascension, see Note 1 and Note 18 of the Company's 2020 Form 10-K. Net services revenue from services provided to Ascension included in the Company’s consolidated statements of operations were (in millions): Three Months Ended March 31, 2021 2020 Ascension $ 215.5 $ 208.4 Amounts included in the Company's consolidated balance sheets for Ascension are (in millions): March 31, 2021 December 31, 2020 Accounts receivable, net of $0.1 million and $0.1 million allowance - related party $ 31.8 $ 30.9 Current portion of customer liabilities $ 10.6 $ 15.3 Non-current portion of customer liabilities $ 15.4 $ 16.3 Total customer liabilities $ 26.0 $ 31.6 |
Deferred Contract Costs
Deferred Contract Costs | 3 Months Ended |
Mar. 31, 2021 | |
Revenue from Contract with Customer [Abstract] | |
Deferred Contract Costs | Revenue Recognition The Company follows the guidance under Topic 606, Revenue from Contracts with Customers (“Topic 606”). Revenue is measured based on consideration specified in a contract with a customer, and excludes any sales incentives and amounts collected on behalf of third parties. The Company recognizes revenue when it satisfies a performance obligation by transferring control over a service to a customer, which is typically over the contact term. Estimates of variable consideration are included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur once the uncertainty is resolved. Disaggregation of Revenue In the following table, revenue is disaggregated by source (in millions): Three Months Ended March 31, 2021 2020 Net operating fees $ 286.1 $ 280.9 Incentive fees 29.0 16.8 Other 27.5 22.8 Net services revenue $ 342.6 $ 320.5 Contract Balances The following table provides information about receivables, contract assets, and contract liabilities from contracts with customers (in millions): March 31, 2021 December 31, 2020 Receivables (1) $ 129.4 $ 122.2 Contract assets (2) 6.7 — Contract liabilities (2) 25.7 28.6 (1) Receivables are included in accounts receivable, net. The balance includes accounts receivable, net - related party. (2) Contract assets and contract liabilities are included in other current assets and customer liabilities, respectively. The contract liabilities balance contains related party amounts, including $3.9 million and $5.6 million of current customer liabilities and $15.4 million and $16.3 million of non-current customer liabilities for the three months ended March 31, 2021 and year ended December 31, 2020, respectively. A receivable is recognized in the period the Company provides services when the Company’s right to consideration is unconditional. Payment terms on invoiced amounts are typically 30-60 days. The Company recognized revenue of $93.7 million and $86.0 million during the three months ended March 31, 2021 and 2020, which amounts were included in contract liabilities at the beginning of the respective periods. These revenue amounts include $88.1 million and $85.0 million for the three months ended March 31, 2021 and 2020, respectively, related to advanced billings which become accounts receivable and contract liabilities on the first day of the respective service period. Transaction Price Allocated to the Remaining Performance Obligation The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period (in millions). The estimated revenue does not include amounts of variable consideration that are constrained. Net operating fees Incentive fees Other Remainder of 2021 $ 83.9 $ 31.4 $ 1.7 2022 70.0 — — 2023 55.0 — — 2024 35.0 — — 2025 11.7 — — 2026 5.6 — — Thereafter — — — Total $ 261.2 $ 31.4 $ 1.7 The amounts presented in the table above include variable fee estimates for the non-cancellable term of the Company's physician groups RCM services contracts, fixed fees which are typically recognized ratably as the performance obligation is satisfied, and incentive fees which are measured cumulatively over the contractually defined performance period. Certain costs associated with the initial phases of customer contracts and the related transition of customer hospitals and physician groups are deferred. These fulfillment costs relate directly to the Company’s responsibilities under the corresponding customer contracts, generate or enhance resources of the Company that will be used in satisfying its performance obligations in the future, and are expected to be recovered through the margins realized. The following table summarizes the breakout of deferred contract costs (in millions): March 31, 2021 December 31, 2020 Prepaid expenses and other current assets $ 4.7 $ 4.5 Other assets 19.5 19.6 Total deferred contract costs $ 24.2 $ 24.1 The associated assets are amortized as services are transferred to the customer over the remaining life of the contracts. For the three months ended March 31, 2021 and 2020, total amortization was $1.2 million and $1.1 million, respectively, and there were no associated impairment losses. |
Segments and Customer Concentra
Segments and Customer Concentrations | 3 Months Ended |
Mar. 31, 2021 | |
Segment Reporting [Abstract] | |
Segments and Customer Concentrations | Segments and Customer Concentrations The Company has determined that it has a single operating segment in accordance with how its business activities are managed and evaluated. All of the Company’s significant operations are organized around the single business of providing end-to-end management services of revenue cycle operations for U.S.-based healthcare providers. Accordingly, for purposes of segment disclosures, the Company has only one reportable segment. Healthcare providers affiliated with Ascension have accounted for a significant portion of the Company’s net services revenue each year since the Company’s formation. For the three months ended March 31, 2021 and 2020, net services revenue from healthcare organizations affiliated with Ascension accounted for 63% and 65% of the Company's total net services revenue, respectively. The loss of customers within the Ascension health system could have a material adverse impact on the Company’s operations. For the three months ended March 31, 2021 and 2020, Intermountain Healthcare accounted for 14% and 15% of the Company's total net services revenue, respectively. As of March 31, 2021 and December 31, 2020, the Company had a concentration of credit risk with Ascension accounting for 25% and 25% of accounts receivable, respectively. |
Derivative Financial Instrument
Derivative Financial Instruments | 3 Months Ended |
Mar. 31, 2021 | |
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |
Derivative Financial Instruments | Derivative Financial InstrumentsThe Company utilizes cash flow hedges to mitigate its currency risk arising from its global delivery resources and to reduce variability in interest cash flows from its outstanding debt. As of March 31, 2021, the Company has recorded $0.6 million of existing gains and $1.8 million of existing losses in accumulated other comprehensive income for the foreign currency hedges and interest rate swaps, respectively. The Company estimates that $0.6 million of gains and $1.3 million of losses reported in accumulated other comprehensive income are expected to be reclassified into earnings within the next 12 months for the foreign currency hedges and interest rate swaps, respectively. The amounts related to foreign currency hedges that were reclassified into cost of services were a net gain of $0.4 million and a net loss of $0.1 million during the three month periods ended March 31, 2021 and 2020, respectively. The amounts related to the interest rate swaps that were reclassified into interest expense were a net loss of $0.5 million and a net gain of $0.1 million during the three month periods ended March 31, 2021 and 2020, respectively. The Company classifies cash flows from its derivative programs as cash flows from operating activities in the consolidated statements of cash flows. As of March 31, 2021, the Company’s currency forward contracts have maturities extending no later than March 31, 2022. The Company's interest rate swaps extend no later than August of 2022. As of March 31, 2021, the notional amounts of the Company's open foreign currency forward contracts and interest rate swaps were approximately $95.1 million and $100.0 million, respectively. As of December 31, 2020, the notional amounts of the Company's open foreign currency forward contracts and interest rate swaps were approximately $55.9 million and $200.0 million, respectively. As of March 31, 2021, the Company held no derivatives, or non-derivative hedging instruments, that were designated in fair value or net investment hedges. Fair values for derivative financial instruments are based on prices computed using third-party valuation models and are classified as Level 2 in accordance with the three-level hierarchy of fair value measurements. |
Subsequent Events
Subsequent Events | 3 Months Ended |
Mar. 31, 2021 | |
Subsequent Events [Abstract] | |
Subsequent Events | Subsequent Events On April 30, 2021, the Company entered into an agreement with Ascension amending the A&R MPSA. The agreement expands R1’s role as the provider of patient experience technologies, and extends R1’s revenue cycle management services agreement with Ascension to 2031. On May 3, 2021, the Company entered into a definitive agreement to acquire VisitPay Inc. (“VisitPay”), a provider of digital payment solutions. The Company will acquire VisitPay for $298.0 million in cash, subject to customary adjustments for working capital, cash, and debt. The Company intends to fund the acquisition and related fees and expenses with the proceeds from additional borrowings and cash on hand. Concurrent with the entry into the definitive agreement to acquire VisitPay, the Company obtained a debt financing commitment letter from Bank of America in the amount of $300.0 million. There is no financing condition linked to the consummation of the acquisition. The agreement contains customary representations, warranties, and closing conditions. The transaction is expected to close in the third quarter of 2021. |
Recent Accounting Pronounceme_2
Recent Accounting Pronouncements (Policies) | 3 Months Ended |
Mar. 31, 2021 | |
Accounting Policies [Abstract] | |
Basis of Presentation | Basis of Presentation The accompanying unaudited consolidated financial statements reflect the Company's financial position as of March 31, 2021, the results of operations of the Company for the three months ended March 31, 2021 and 2020, and the cash flows of the Company for the three months ended March 31, 2021 and 2020. These financial statements include the accounts of R1 RCM Inc. and its wholly-owned subsidiaries. All material intercompany amounts have been eliminated in consolidation. These financial statements have been prepared in accordance with United States generally accepted accounting principles (“GAAP”) for interim financial reporting and as required by the rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”). Accordingly, certain information and footnote disclosures required for complete financial statements are not included herein. In the opinion of management, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the interim financial information, have been included. Operating results for the three months ended March 31, 2021 are not necessarily indicative of the results that may be expected for any other interim period or for the fiscal year ending December 31, 2021. |
Recently Issued Accounting Standards and Disclosures | Recently Issued Accounting Standards and Disclosures No new accounting pronouncements issued or effective during the fiscal year had, or is expected to have, a material impact on the Company’s consolidated financial statements. |
Accounts Receivable and Allowance for Credit Losses | Accounts Receivable and Allowance for Credit LossesAccounts receivable is comprised of unpaid balances pertaining to modular services and end-to-end revenue cycle management (“RCM”) customers, net receivable balances for end-to-end RCM customers after considering cost reimbursements owed to such customers, including related accrued balances, and amounts due from physician RCM and practice management customers. |
Revenue Recognition | Revenue RecognitionThe Company follows the guidance under Topic 606, Revenue from Contracts with Customers (“Topic 606”). Revenue is measured based on consideration specified in a contract with a customer, and excludes any sales incentives and amounts collected on behalf of third parties. The Company recognizes revenue when it satisfies a performance obligation by transferring control over a service to a customer, which is typically over the contact term. Estimates of variable consideration are included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur once the uncertainty is resolved. |
Acquisitions (Tables)
Acquisitions (Tables) | 3 Months Ended |
Mar. 31, 2021 | |
Business Combinations [Abstract] | |
Schedule of Assets Acquired and Liabilities Assumed | The fair value of assets acquired and liabilities assumed is (in millions): Purchase Price Allocation Total purchase consideration $ 197.0 Allocation of consideration to assets acquired and liabilities assumed: Cash and cash equivalents $ 2.9 Accounts receivable 2.8 Prepaid expenses and other current assets 1.2 Property, equipment and software 0.3 Operating lease right-of-use assets 1.2 Intangible assets 86.1 Goodwill 125.8 Accounts payable (0.2) Current portion of customer liabilities (4.0) Accrued compensation and benefits (1.6) Current portion of operating lease liabilities (0.5) Other accrued expenses (0.4) Non-current portion of operating lease liabilities (0.7) Other non-current liabilities (5.0) Deferred income tax liabilities (10.9) Net assets acquired $ 197.0 |
Schedule of Pro Forma Results | The following table summarizes, on a pro forma basis, the combined results of the Company as though the SCI and RevWorks acquisitions had occurred as of January 1, 2019. These pro forma results are not necessarily indicative of either the actual consolidated results had the acquisitions occurred as of January 1, 2019 or of the future consolidated operating results for any period. Pro forma results are (in millions): Three Months Ended March 31, 2020 Net services revenue $ 349.6 Net income $ 17.3 |
Accounts Receivable and Allow_2
Accounts Receivable and Allowance for Credit Losses (Tables) | 3 Months Ended |
Mar. 31, 2021 | |
Receivables [Abstract] | |
Schedule of Allowance for Credit Losses | Movements in the allowance for credit losses are as follows (in millions): Three Months Ended March 31, 2021 2020 Beginning balance $ 3.8 $ 2.8 Cumulative effect of ASC 326 — 1.1 Provision (recoveries) 0.1 0.8 Ending balance $ 3.9 $ 4.7 |
Property, Equipment, and Softwa
Property, Equipment, and Software (Tables) | 3 Months Ended |
Mar. 31, 2021 | |
Property, Plant and Equipment [Abstract] | |
Schedule of Property, Equipment and Software | Property, equipment and software consist of the following (in millions): March 31, 2021 December 31, 2020 Buildings and land $ 4.6 $ 4.6 Computer and other equipment 56.6 55.0 Leasehold improvements 23.3 23.2 Software 142.3 135.7 Office furniture 6.4 6.4 Property, equipment and software, gross 233.2 224.9 Less accumulated depreciation and amortization (144.2) (131.2) Property, equipment and software, net $ 89.0 $ 93.7 |
Summary Depreciation and Amortization Expense | The following table summarizes the allocation of depreciation and amortization expense between cost of services and selling, general and administrative expenses (in millions): Three Months Ended March 31, 2021 2020 Cost of services $ 12.7 $ 10.9 Selling, general and administrative 0.8 1.3 Total depreciation and amortization $ 13.5 $ 12.2 |
Leases (Tables)
Leases (Tables) | 3 Months Ended |
Mar. 31, 2021 | |
Leases [Abstract] | |
Schedules of Components of Lease Costs and Supplemental Cash Flow Information | The components of lease costs are as follows (in millions): Three Months Ended March 31, 2021 2020 Operating lease cost $ 4.1 $ 4.9 Finance lease cost: Amortization of right-of-use (“ROU”) assets 0.1 0.2 Interest on lease liabilities — 0.1 Sublease income (0.6) (0.6) Total lease cost $ 3.6 $ 4.6 Supplemental cash flow information related to leases are as follows (in millions): Three Months Ended March 31, 2021 2020 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows for operating leases $ 9.4 $ 4.9 Operating cash flows for finance leases — 0.1 Financing cash flows for finance leases — 0.6 ROU assets obtained in exchange for lease obligations: Operating leases 5.6 1.7 |
Schedule of Supplemental Balance Sheet Information | Supplemental balance sheet information related to leases are as follows: March 31, 2021 December 31, 2020 Weighted average remaining lease term: Operating leases 7 years 7 years Finance leases 3 years 2 years Weighted average incremental borrowing rate: Operating leases 8.99 % 8.94 % Finance leases 6.71 % 6.62 % |
Schedule of Operating Lease Maturity | Maturities of lease liabilities as of March 31, 2021 are as follows (in millions): Operating Leases Finance Leases Remainder of 2021 $ 14.0 $ 0.1 2022 16.0 0.1 2023 15.2 — 2024 15.3 — 2025 15.2 — 2026 12.0 — Thereafter 22.1 — Total 109.8 0.2 Less: Imputed interest 29.3 — Present value of lease liabilities $ 80.5 $ 0.2 |
Schedule of Finance Lease Maturity | Maturities of lease liabilities as of March 31, 2021 are as follows (in millions): Operating Leases Finance Leases Remainder of 2021 $ 14.0 $ 0.1 2022 16.0 0.1 2023 15.2 — 2024 15.3 — 2025 15.2 — 2026 12.0 — Thereafter 22.1 — Total 109.8 0.2 Less: Imputed interest 29.3 — Present value of lease liabilities $ 80.5 $ 0.2 |
Intangible Assets (Tables)
Intangible Assets (Tables) | 3 Months Ended |
Mar. 31, 2021 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Schedule of Intangible Assets | The following table provides the gross carrying value and accumulated amortization for each major class of intangible asset at March 31, 2021 and December 31, 2020 (in millions): March 31, 2021 December 31, 2020 Gross Carrying Value Accumulated Amortization Net Book Value Gross Carrying Value Accumulated Amortization Net Book Value Customer relationships $ 97.7 $ (16.2) $ 81.5 $ 97.7 $ (14.7) $ 83.0 Technology 101.7 (16.5) 85.2 101.7 (13.6) 88.1 Total intangible assets $ 199.4 $ (32.7) $ 166.7 $ 199.4 $ (28.3) $ 171.1 |
Schedule of Estimated Annual Amortization Expense | Estimated annual amortization expense related to intangible assets with definite lives as of March 31, 2021 is as follows (in millions): Remainder of 2021 $ 12.9 2022 17.3 2023 17.3 2024 15.5 2025 14.5 2026 14.5 Thereafter 74.7 Total $ 166.7 |
Goodwill (Tables)
Goodwill (Tables) | 3 Months Ended |
Mar. 31, 2021 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Schedule of Changes in Carrying Value of Goodwill | Changes in the carrying amount of goodwill for the three months ended March 31, 2021 were (in millions): Goodwill Balance as of December 31, 2020 $ 375.3 Measurement period adjustments 0.2 Balance as of March 31, 2021 $ 375.5 |
Revenue Recognition (Tables)
Revenue Recognition (Tables) | 3 Months Ended |
Mar. 31, 2021 | |
Revenue from Contract with Customer [Abstract] | |
Schedule of Disaggregated Revenue By Source | In the following table, revenue is disaggregated by source (in millions): Three Months Ended March 31, 2021 2020 Net operating fees $ 286.1 $ 280.9 Incentive fees 29.0 16.8 Other 27.5 22.8 Net services revenue $ 342.6 $ 320.5 |
Schedule of Assets and Liabilities | The following table provides information about receivables, contract assets, and contract liabilities from contracts with customers (in millions): March 31, 2021 December 31, 2020 Receivables (1) $ 129.4 $ 122.2 Contract assets (2) 6.7 — Contract liabilities (2) 25.7 28.6 (1) Receivables are included in accounts receivable, net. The balance includes accounts receivable, net - related party. |
Schedule of Transaction Price Allocated to the Remaining Performance Obligation | The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period (in millions). The estimated revenue does not include amounts of variable consideration that are constrained. Net operating fees Incentive fees Other Remainder of 2021 $ 83.9 $ 31.4 $ 1.7 2022 70.0 — — 2023 55.0 — — 2024 35.0 — — 2025 11.7 — — 2026 5.6 — — Thereafter — — — Total $ 261.2 $ 31.4 $ 1.7 |
Debt (Tables)
Debt (Tables) | 3 Months Ended |
Mar. 31, 2021 | |
Debt Disclosure [Abstract] | |
Schedule of Carrying Values Long-Term Debt | The carrying amounts of debt consist of the following (in millions): March 31, 2021 December 31, 2020 Senior Revolver $ 70.0 $ 70.0 Senior Term Loan 478.1 484.6 Unamortized discount and issuance costs (2.4) (2.6) Total debt 545.7 552.0 Less: Current maturities (35.5) (32.3) Total long-term debt $ 510.2 $ 519.7 |
Scheduled Maturities of Long-term Debt | Scheduled maturities of the Company’s long-term debt are summarized as follows (in millions): Scheduled Maturities Remainder of 2021 $ 25.8 2022 38.7 2023 45.2 2024 438.4 Total $ 548.1 |
Share-Based Compensation (Table
Share-Based Compensation (Tables) | 3 Months Ended |
Mar. 31, 2021 | |
Share-based Payment Arrangement [Abstract] | |
Schedule of Share-based Compensation Expense | Total share-based compensation costs that have been included in the Company’s consolidated statements of operations were as follows (in millions): Three Months Ended March 31, 2021 2020 Share-Based Compensation Expense Allocation Details: Cost of services $ 7.3 $ 1.9 Selling, general and administrative 5.4 2.9 Other — — Total share-based compensation expense $ 12.7 $ 4.8 |
Summary of Valuation Assumptions | The following table sets forth the significant assumptions used in the Black-Scholes option pricing model and the Monte Carlo simulations and the calculation of share-based compensation expense for the three months ended March 31, 2021 and 2020: Three Months Ended March 31, 2021 2020 Expected dividend yield —% —% Risk-free interest rate 0.4% 1.7% Expected volatility 43% 43% Expected term (in years) 5.5 5.5 |
Schedule of Stock Options Activity | A summary of the options activity during the three months ended March 31, 2021 is shown below: Options Weighted- Outstanding at December 31, 2020 6,220,971 $ 3.68 Granted 1,625 23.49 Exercised (539,795) 6.47 Canceled/forfeited (1,040) 3.85 Expired — — Outstanding at March 31, 2021 5,681,761 $ 3.42 Outstanding, vested and exercisable at March 31, 2021 4,782,897 $ 3.41 Outstanding, vested and exercisable at December 31, 2020 5,230,690 $ 3.73 |
Schedule of Non-Options Awards Activity | A summary of the RSU and PBRSU activity during the three months ended March 31, 2021 is shown below: Weighted- RSUs PBRSUs RSU PBRSU Outstanding and unvested at December 31, 2020 2,108,447 2,917,071 $ 9.87 $ 11.35 Granted 2,719 290,354 23.77 25.09 Vested (6,497) — 10.80 — Forfeited (41,381) (646) 12.99 5.34 Outstanding and unvested at March 31, 2021 2,063,288 3,206,779 $ 9.82 $ 12.59 Shares surrendered for taxes for the three months ended March 31, 2021 2,201 — Cost of shares surrendered for taxes for the three months ended March 31, 2021 (in millions) $ — $ — Shares surrendered for taxes for the three months ended March 31, 2020 545 — Cost of shares surrendered for taxes for the three months ended March 31, 2020 (in millions) $ — $ — |
Other Expenses (Tables)
Other Expenses (Tables) | 3 Months Ended |
Mar. 31, 2021 | |
Other Income and Expenses [Abstract] | |
Schedule of Other Expenses | Other expenses consist of the following (in millions): Three Months Ended March 31, 2021 2020 Severance and related employee benefits $ 1.5 $ 1.1 Strategic initiatives (1) 6.5 3.2 Facility-exit charges (2) 1.5 0.4 Other (3) 3.5 4.0 Total other expenses $ 13.0 $ 8.7 (1) Costs related to evaluating, pursuing, and integrating acquisitions, performing portfolio and capital structure analyses and transactions, and other inorganic business projects as part of the Company’s growth strategy. Costs include vendor spend, employee time and expenses spent on activities, severance and retention amounts associated with integration activities, and changes to contingent consideration related to acquisitions. For the three months ended March 31, 2021, $0.5 million of contingent consideration changes were included. (2) As part of evaluating the Company’s footprint, R1 has exited certain leased facilities. Costs include asset impairment charges and other costs related to exited leased facilities. (3) For the three months ended March 31, 2021 and 2020, includes $1.7 million and $2.6 million, respectively, of expenses related to the COVID-19 pandemic, inclusive of appreciation bonuses for the Company’s front-line employees, pandemic response mobilization efforts, telemedicine and testing costs for employees, and other costs related to the COVID-19 pandemic. |
8.00% Series A Convertible Pr_2
8.00% Series A Convertible Preferred Stock (Tables) | 3 Months Ended |
Mar. 31, 2021 | |
Temporary Equity Disclosure [Abstract] | |
Summary of Preferred Stock Activity | The following summarizes the preferred stock activity for the three months ended March 31, 2021 (in millions, except per share data): Preferred Stock Shares Issued and Outstanding Carrying Value Balance at December 31, 2020 288,497 $ 251.5 Dividends paid/accrued dividends 5,769 — Conversion of preferred stock (294,266) (251.5) Balance at March 31, 2021 — $ — |
Earnings (Loss) Per Share (Tabl
Earnings (Loss) Per Share (Tables) | 3 Months Ended |
Mar. 31, 2021 | |
Earnings Per Share [Abstract] | |
Schedule of Basic and Diluted Net Income (Loss) Per Common Share | Basic and diluted net income (loss) per common share are calculated as follows (in millions, except share and per share data): Three Months Ended 2021 2020 Basic EPS: Net income $ 25.8 $ 18.2 Less dividends on preferred shares (1) (592.3) (5.4) Less income allocated to preferred shareholders — (6.2) Net income (loss) available/(allocated) to common shareholders - basic $ (566.5) $ 6.6 Diluted EPS: Net income $ 25.8 $ 18.2 Less dividends on preferred shares (1) (592.3) (5.4) Less income allocated to preferred shareholders — (5.0) Net income (loss) available/(allocated) to common shareholders - diluted $ (566.5) $ 7.8 Basic weighted-average common shares 239,290,145 114,441,043 Add: Effect of dilutive equity awards — 11,893,514 Add: Effect of dilutive warrants — 43,285,621 Diluted weighted average common shares 239,290,145 169,620,178 Net income (loss) per common share (basic) $ (2.37) $ 0.06 Net income (loss) per common share (diluted) $ (2.37) $ 0.05 (1) The 2021 dividend on preferred shares includes amounts related to the conversion of the preferred shares. See Note 15, 8.00% Series A Convertible Preferred Stock, to the consolidated financial statements included in this Quarterly Report on Form 10-Q for more information. |
Related Party Transactions (Tab
Related Party Transactions (Tables) | 3 Months Ended |
Mar. 31, 2021 | |
Related Party Transactions [Abstract] | |
Schedule of Related Party Transactions | Net services revenue from services provided to Ascension included in the Company’s consolidated statements of operations were (in millions): Three Months Ended March 31, 2021 2020 Ascension $ 215.5 $ 208.4 Amounts included in the Company's consolidated balance sheets for Ascension are (in millions): March 31, 2021 December 31, 2020 Accounts receivable, net of $0.1 million and $0.1 million allowance - related party $ 31.8 $ 30.9 Current portion of customer liabilities $ 10.6 $ 15.3 Non-current portion of customer liabilities $ 15.4 $ 16.3 Total customer liabilities $ 26.0 $ 31.6 |
Deferred Contract Costs (Tables
Deferred Contract Costs (Tables) | 3 Months Ended |
Mar. 31, 2021 | |
Revenue from Contract with Customer [Abstract] | |
Summary of Deferred Contract Costs | The following table summarizes the breakout of deferred contract costs (in millions): March 31, 2021 December 31, 2020 Prepaid expenses and other current assets $ 4.7 $ 4.5 Other assets 19.5 19.6 Total deferred contract costs $ 24.2 $ 24.1 |
Business Description and Basi_2
Business Description and Basis of Presentation - Narrative (Details) - Disposal Group, Disposed of by Sale, Not Discontinued Operations - EMS Disposition $ in Millions | Oct. 30, 2020USD ($) |
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | |
Sale of EMS business, disposition price | $ 140 |
Sale of EMS business, hold-back amount included in disposition price | $ 5 |
Sale of EMS business, hold-back amount, settlement period from date of the disposition | 1 year |
Sale of EMS business, total sale price, net of cost to sell | $ 132.7 |
Sale of EMS business, goodwill | 7.1 |
Sale of EMS business, gain recognized | $ 55.7 |
Acquisitions - Narrative (Detai
Acquisitions - Narrative (Details) | Sep. 03, 2022USD ($) | Sep. 03, 2021USD ($) | Aug. 03, 2020USD ($)payment | Apr. 01, 2020USD ($) | Sep. 03, 2022USD ($) | Mar. 31, 2021USD ($) | Dec. 31, 2020USD ($) |
Business Acquisition [Line Items] | |||||||
Goodwill | $ 375,500,000 | $ 375,300,000 | |||||
SCI Acquisition | |||||||
Business Acquisition [Line Items] | |||||||
Purchase price | $ 190,000,000 | ||||||
Other non-current liabilities, note payable | 5,000,000 | ||||||
Purchase consideration | 197,000,000 | ||||||
Goodwill | 125,800,000 | ||||||
SCI Acquisition | Earn-out Provision | |||||||
Business Acquisition [Line Items] | |||||||
Earn-out provision, value | $ 4,800,000 | $ 10,000,000 | |||||
RevWorks | |||||||
Business Acquisition [Line Items] | |||||||
Purchase consideration | $ 30,000,000 | ||||||
Purchase price, payment | $ 5,000,000 | ||||||
Number of deferred payments | payment | 2 | ||||||
Contractual deferred payments | $ 24,300,000 | ||||||
Goodwill | 3,600,000 | ||||||
RevWorks | Customer relationships | |||||||
Business Acquisition [Line Items] | |||||||
Assets acquired | 2,800,000 | ||||||
RevWorks | Subsequent Event | Forecast | |||||||
Business Acquisition [Line Items] | |||||||
Purchase price, payment | $ 12,500,000 | $ 12,500,000 | $ 25,000,000 | ||||
RevWorks | Cerner | |||||||
Business Acquisition [Line Items] | |||||||
Contingent consideration asset, (up to) | 25,000,000 | ||||||
Asset, contingently returnable consideration | 22,300,000 | ||||||
RevWorks | Cerner | Prepaid expenses and other current assets | |||||||
Business Acquisition [Line Items] | |||||||
Asset, contingently returnable consideration | 11,500,000 | ||||||
RevWorks | Cerner | Other noncurrent assets | |||||||
Business Acquisition [Line Items] | |||||||
Asset, contingently returnable consideration | $ 10,800,000 |
Acquisitions - Fair Value of As
Acquisitions - Fair Value of Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Millions | Apr. 01, 2020 | Mar. 31, 2021 | Dec. 31, 2020 |
Allocation of consideration to assets acquired and liabilities assumed: | |||
Goodwill | $ 375.5 | $ 375.3 | |
SCI Acquisition | |||
Business Acquisition [Line Items] | |||
Total purchase consideration | $ 197 | ||
Allocation of consideration to assets acquired and liabilities assumed: | |||
Cash and cash equivalents | 2.9 | ||
Accounts receivable | 2.8 | ||
Prepaid expenses and other current assets | 1.2 | ||
Property, equipment and software | 0.3 | ||
Operating lease right-of-use assets | 1.2 | ||
Intangible assets | 86.1 | ||
Goodwill | 125.8 | ||
Accounts payable | (0.2) | ||
Current portion of customer liabilities | (4) | ||
Accrued compensation and benefits | (1.6) | ||
Current portion of operating lease liabilities | (0.5) | ||
Other accrued expenses | (0.4) | ||
Non-current portion of operating lease liabilities | (0.7) | ||
Other non-current liabilities | (5) | ||
Deferred income tax liabilities | (10.9) | $ (10.9) | |
Net assets acquired | $ 197 |
Acquisitions - Pro Forma Result
Acquisitions - Pro Forma Results (Details) - RevWorks $ in Millions | 3 Months Ended |
Mar. 31, 2020USD ($) | |
Business Acquisition [Line Items] | |
Net services revenue | $ 349.6 |
Net income | $ 17.3 |
Accounts Receivable and Allow_3
Accounts Receivable and Allowance for Credit Losses - Schedule of Allowance for Credit Losses (Details) - USD ($) $ in Millions | 3 Months Ended | 12 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | Dec. 31, 2019 | |
Accounts Receivable, Allowance for Credit Loss [Roll Forward] | |||
Beginning balance | $ 3.8 | $ 2.8 | |
Cumulative effect of ASC 326 adoption | $ 3.9 | $ 4.7 | $ 2.8 |
Accounting Standards Update [Extensible List] | us-gaap:AccountingStandardsUpdate201613Member | us-gaap:AccountingStandardsUpdate201613Member | us-gaap:AccountingStandardsUpdate201613Member |
Provision (recoveries) | $ 0.1 | $ 0.8 | |
Ending balance | 3.9 | 4.7 | $ 2.8 |
Cumulative Effect, Period of Adoption, Adjustment | |||
Accounts Receivable, Allowance for Credit Loss [Roll Forward] | |||
Beginning balance | 0 | 1.1 | |
Cumulative effect of ASC 326 adoption | $ 0 | $ 1.1 | 1.1 |
Ending balance | $ 1.1 |
Property, Equipment, and Soft_2
Property, Equipment, and Software - Schedule of Property, Equipment and Software (Details) - USD ($) $ in Millions | Mar. 31, 2021 | Dec. 31, 2020 |
Property, Plant and Equipment [Line Items] | ||
Property, equipment and software, gross | $ 233.2 | $ 224.9 |
Less accumulated depreciation and amortization | (144.2) | (131.2) |
Property, equipment and software, net | 89 | 93.7 |
Buildings and land | ||
Property, Plant and Equipment [Line Items] | ||
Property, equipment and software, gross | 4.6 | 4.6 |
Computer and other equipment | ||
Property, Plant and Equipment [Line Items] | ||
Property, equipment and software, gross | 56.6 | 55 |
Leasehold improvements | ||
Property, Plant and Equipment [Line Items] | ||
Property, equipment and software, gross | 23.3 | 23.2 |
Software | ||
Property, Plant and Equipment [Line Items] | ||
Property, equipment and software, gross | 142.3 | 135.7 |
Office furniture | ||
Property, Plant and Equipment [Line Items] | ||
Property, equipment and software, gross | $ 6.4 | $ 6.4 |
Property, Equipment, and Soft_3
Property, Equipment, and Software - Allocation of Depreciation and Amortization Expense between Cost of Services and Selling, General and Administrative Expenses (Details) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Property, Plant and Equipment [Line Items] | ||
Total depreciation and amortization | $ 13.5 | $ 12.2 |
Cost of services | ||
Property, Plant and Equipment [Line Items] | ||
Total depreciation and amortization | 12.7 | 10.9 |
Selling, general and administrative | ||
Property, Plant and Equipment [Line Items] | ||
Total depreciation and amortization | $ 0.8 | $ 1.3 |
Leases - Schedule of Lease Cost
Leases - Schedule of Lease Costs (Details) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Leases [Abstract] | ||
Operating lease cost | $ 4.1 | $ 4.9 |
Finance lease cost: | ||
Amortization of right-of-use (“ROU”) assets | 0.1 | 0.2 |
Interest on lease liabilities | 0 | 0.1 |
Sublease income | (0.6) | (0.6) |
Total lease cost | $ 3.6 | $ 4.6 |
Leases - Schedule of Supplement
Leases - Schedule of Supplemental Cash Flow Information (Details) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Cash paid for amounts included in the measurement of lease liabilities: | ||
Operating cash flows for operating leases | $ 9.4 | $ 4.9 |
Operating cash flows for finance leases | 0 | 0.1 |
Financing cash flows for finance leases | 0 | 0.6 |
ROU assets obtained in exchange for lease obligations: | ||
Operating leases | $ 5.6 | $ 1.7 |
Leases - Schedule of Suppleme_2
Leases - Schedule of Supplemental Balance Sheet Information (Details) | Mar. 31, 2021 | Dec. 31, 2020 |
Weighted average remaining lease term: | ||
Operating leases | 7 years | 7 years |
Finance leases | 3 years | 2 years |
Weighted average incremental borrowing rate: | ||
Operating leases | 8.99% | 8.94% |
Finance leases | 6.71% | 6.62% |
Leases - Schedule of Operating
Leases - Schedule of Operating and Finance Lease Maturity (Details) $ in Millions | Mar. 31, 2021USD ($) |
Operating Leases | |
Remainder of 2021 | $ 14 |
2022 | 16 |
2023 | 15.2 |
2024 | 15.3 |
2025 | 15.2 |
2026 | 12 |
Thereafter | 22.1 |
Total | 109.8 |
Less: | |
Imputed interest | 29.3 |
Present value of lease liabilities | 80.5 |
Finance Leases | |
Remainder of 2021 | 0.1 |
2022 | 0.1 |
2023 | 0 |
2024 | 0 |
2025 | 0 |
2026 | 0 |
Thereafter | 0 |
Total | 0.2 |
Less: | |
Imputed interest | 0 |
Present value of lease liabilities | $ 0.2 |
Intangible Assets - Components
Intangible Assets - Components of Intangible Assets (Details) - USD ($) $ in Millions | Mar. 31, 2021 | Dec. 31, 2020 |
Finite-Lived Intangible Assets [Line Items] | ||
Gross Carrying Value | $ 199.4 | $ 199.4 |
Accumulated Amortization | (32.7) | (28.3) |
Total | 166.7 | 171.1 |
Customer relationships | ||
Finite-Lived Intangible Assets [Line Items] | ||
Gross Carrying Value | 97.7 | 97.7 |
Accumulated Amortization | (16.2) | (14.7) |
Total | 81.5 | 83 |
Technology | ||
Finite-Lived Intangible Assets [Line Items] | ||
Gross Carrying Value | 101.7 | 101.7 |
Accumulated Amortization | (16.5) | (13.6) |
Total | $ 85.2 | $ 88.1 |
Intangible Assets - Narrative (
Intangible Assets - Narrative (Details) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Goodwill and Intangible Assets Disclosure [Abstract] | ||
Intangible asset amortization expense | $ 4.4 | $ 3.5 |
Intangible Assets - Future Amor
Intangible Assets - Future Amortization (Details) - USD ($) $ in Millions | Mar. 31, 2021 | Dec. 31, 2020 |
Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract] | ||
Remainder of 2021 | $ 12.9 | |
2022 | 17.3 | |
2023 | 17.3 | |
2024 | 15.5 | |
2025 | 14.5 | |
2026 | 14.5 | |
Thereafter | 74.7 | |
Total | $ 166.7 | $ 171.1 |
Goodwill - Schedule of Changes
Goodwill - Schedule of Changes in Carrying Value of Goodwill (Details) $ in Millions | 3 Months Ended |
Mar. 31, 2021USD ($) | |
Goodwill [Roll Forward] | |
Balance as of December 31, 2020 | $ 375.3 |
Measurement period adjustments | 0.2 |
Balance as of March 31, 2021 | $ 375.5 |
Revenue Recognition - Schedule
Revenue Recognition - Schedule of Disaggregated Revenue by Source (Details) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Disaggregation of Revenue [Line Items] | ||
Net services revenue | $ 342.6 | $ 320.5 |
Net operating fees | ||
Disaggregation of Revenue [Line Items] | ||
Net services revenue | 286.1 | 280.9 |
Incentive fees | ||
Disaggregation of Revenue [Line Items] | ||
Net services revenue | 29 | 16.8 |
Other | ||
Disaggregation of Revenue [Line Items] | ||
Net services revenue | $ 27.5 | $ 22.8 |
Revenue Recognition - Schedul_2
Revenue Recognition - Schedule of Contract Balances (Details) - USD ($) $ in Millions | Mar. 31, 2021 | Dec. 31, 2020 |
Disaggregation of Revenue [Line Items] | ||
Receivables, including related party | $ 129.4 | $ 122.2 |
Contract assets | 6.7 | 0 |
Non-current customer liabilities, related party | 15.4 | 16.3 |
Contract With Customer Liability | ||
Disaggregation of Revenue [Line Items] | ||
Contract liabilities | 25.7 | 28.6 |
Investor | ||
Disaggregation of Revenue [Line Items] | ||
Current customer liabilities, related party | $ 3.9 | $ 5.6 |
Revenue Recognition - Narrative
Revenue Recognition - Narrative (Details) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Disaggregation of Revenue [Line Items] | ||
Revenue recognized | $ 93.7 | $ 86 |
Accounts Receivable | ||
Disaggregation of Revenue [Line Items] | ||
Revenue recognized, advanced billings | $ 88.1 | $ 85 |
Revenue Recognition - Transacti
Revenue Recognition - Transaction Price Allocated to the Remaining Performance Obligation (Details) $ in Millions | Mar. 31, 2021USD ($) |
Net operating fees | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | |
Revenue expected to be recognized in the future related to unsatisfied performance obligations, amount | $ 261.2 |
Incentive fees | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | |
Revenue expected to be recognized in the future related to unsatisfied performance obligations, amount | 31.4 |
Other | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | |
Revenue expected to be recognized in the future related to unsatisfied performance obligations, amount | $ 1.7 |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-04-01 | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | |
Revenue expected to be recognized in the future related to unsatisfied performance obligations, period | 3 months |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-04-01 | Net operating fees | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | |
Revenue expected to be recognized in the future related to unsatisfied performance obligations, amount | $ 83.9 |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-04-01 | Incentive fees | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | |
Revenue expected to be recognized in the future related to unsatisfied performance obligations, amount | 31.4 |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-04-01 | Other | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | |
Revenue expected to be recognized in the future related to unsatisfied performance obligations, amount | $ 1.7 |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01 | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | |
Revenue expected to be recognized in the future related to unsatisfied performance obligations, period | 1 year |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01 | Net operating fees | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | |
Revenue expected to be recognized in the future related to unsatisfied performance obligations, amount | $ 70 |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01 | Incentive fees | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | |
Revenue expected to be recognized in the future related to unsatisfied performance obligations, amount | 0 |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01 | Other | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | |
Revenue expected to be recognized in the future related to unsatisfied performance obligations, amount | $ 0 |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01 | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | |
Revenue expected to be recognized in the future related to unsatisfied performance obligations, period | 1 year |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01 | Net operating fees | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | |
Revenue expected to be recognized in the future related to unsatisfied performance obligations, amount | $ 55 |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01 | Incentive fees | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | |
Revenue expected to be recognized in the future related to unsatisfied performance obligations, amount | 0 |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01 | Other | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | |
Revenue expected to be recognized in the future related to unsatisfied performance obligations, amount | $ 0 |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01 | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | |
Revenue expected to be recognized in the future related to unsatisfied performance obligations, period | 1 year |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01 | Net operating fees | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | |
Revenue expected to be recognized in the future related to unsatisfied performance obligations, amount | $ 35 |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01 | Incentive fees | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | |
Revenue expected to be recognized in the future related to unsatisfied performance obligations, amount | 0 |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01 | Other | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | |
Revenue expected to be recognized in the future related to unsatisfied performance obligations, amount | $ 0 |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01 | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | |
Revenue expected to be recognized in the future related to unsatisfied performance obligations, period | 1 year |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01 | Net operating fees | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | |
Revenue expected to be recognized in the future related to unsatisfied performance obligations, amount | $ 11.7 |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01 | Incentive fees | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | |
Revenue expected to be recognized in the future related to unsatisfied performance obligations, amount | 0 |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01 | Other | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | |
Revenue expected to be recognized in the future related to unsatisfied performance obligations, amount | $ 0 |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-01 | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | |
Revenue expected to be recognized in the future related to unsatisfied performance obligations, period | 1 year |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-01 | Net operating fees | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | |
Revenue expected to be recognized in the future related to unsatisfied performance obligations, amount | $ 5.6 |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-01 | Incentive fees | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | |
Revenue expected to be recognized in the future related to unsatisfied performance obligations, amount | 0 |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-01 | Other | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | |
Revenue expected to be recognized in the future related to unsatisfied performance obligations, amount | $ 0 |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2027-01-01 | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | |
Revenue expected to be recognized in the future related to unsatisfied performance obligations, period | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2027-01-01 | Net operating fees | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | |
Revenue expected to be recognized in the future related to unsatisfied performance obligations, amount | $ 0 |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2027-01-01 | Incentive fees | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | |
Revenue expected to be recognized in the future related to unsatisfied performance obligations, amount | 0 |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2027-01-01 | Other | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | |
Revenue expected to be recognized in the future related to unsatisfied performance obligations, amount | $ 0 |
Debt - Carrying Amounts of Debt
Debt - Carrying Amounts of Debt (Details) - USD ($) $ in Millions | Mar. 31, 2021 | Dec. 31, 2020 |
Debt Instrument [Line Items] | ||
Long-term Debt | $ 548.1 | |
Unamortized discount and issuance costs | (2.4) | $ (2.6) |
Total debt | 545.7 | 552 |
Less: Current maturities | (35.5) | (32.3) |
Total long-term debt | 510.2 | 519.7 |
Line of Credit | Senior Revolver | ||
Debt Instrument [Line Items] | ||
Long-term Debt | 70 | 70 |
Line of Credit | Senior Term Loan | ||
Debt Instrument [Line Items] | ||
Long-term Debt | $ 478.1 | $ 484.6 |
Debt - Narrative (Details)
Debt - Narrative (Details) - USD ($) | Jan. 19, 2021 | Jan. 15, 2021 | Jun. 26, 2019 | Mar. 31, 2021 | Mar. 31, 2020 | Dec. 31, 2020 | Jan. 13, 2021 | Mar. 20, 2020 |
Debt Instrument [Line Items] | ||||||||
Cash paid, stock conversion (not to exceed) | $ 105,000,000 | $ 0 | ||||||
Long-term debt | $ 548,100,000 | |||||||
Redeemable Convertible Preferred Stock | ||||||||
Debt Instrument [Line Items] | ||||||||
Preferred stock, dividend rate (percentage) | 8.00% | 8.00% | ||||||
TCP-ASC ACHI Series LLLP | ||||||||
Debt Instrument [Line Items] | ||||||||
Cash paid, stock conversion (not to exceed) | $ 105,000,000 | |||||||
TCP-ASC ACHI Series LLLP | Redeemable Convertible Preferred Stock | ||||||||
Debt Instrument [Line Items] | ||||||||
Preferred stock, dividend rate (percentage) | 8.00% | 8.00% | ||||||
Disposal Group, Disposed of by Sale, Not Discontinued Operations | EMS Disposition | ||||||||
Debt Instrument [Line Items] | ||||||||
Net proceeds from disposition, obligation waived | $ 135,000,000 | |||||||
Line of Credit | ||||||||
Debt Instrument [Line Items] | ||||||||
Interest rate | 2.36% | |||||||
Line of Credit | Minimum | ||||||||
Debt Instrument [Line Items] | ||||||||
Commitment fee | 0.30% | |||||||
Line of Credit | Maximum | ||||||||
Debt Instrument [Line Items] | ||||||||
Commitment fee | 0.50% | |||||||
Line of Credit | Federal Funds Rate | ||||||||
Debt Instrument [Line Items] | ||||||||
Basis spread on variable rate basis | 0.50% | |||||||
Line of Credit | Eurodollar Rate | ||||||||
Debt Instrument [Line Items] | ||||||||
Variable rate basis, minimum | 0.00% | |||||||
Line of Credit | Eurodollar Rate | Interest Rate Option - Basis Spread One | ||||||||
Debt Instrument [Line Items] | ||||||||
Basis spread on variable rate basis | 1.00% | |||||||
Line of Credit | Eurodollar Rate | Interest Rate Option - Basis Spread One | Minimum | ||||||||
Debt Instrument [Line Items] | ||||||||
Basis spread on variable rate basis | 0.75% | |||||||
Line of Credit | Eurodollar Rate | Interest Rate Option - Basis Spread One | Maximum | ||||||||
Debt Instrument [Line Items] | ||||||||
Basis spread on variable rate basis | 1.75% | |||||||
Line of Credit | Eurodollar Rate | Interest Rate Option Two | ||||||||
Debt Instrument [Line Items] | ||||||||
Variable rate basis, minimum | 0.00% | |||||||
Line of Credit | Eurodollar Rate | Interest Rate Option Two | Minimum | ||||||||
Debt Instrument [Line Items] | ||||||||
Basis spread on variable rate basis | 1.75% | |||||||
Line of Credit | Eurodollar Rate | Interest Rate Option Two | Maximum | ||||||||
Debt Instrument [Line Items] | ||||||||
Basis spread on variable rate basis | 2.75% | |||||||
Line of Credit | Senior Term Loan | ||||||||
Debt Instrument [Line Items] | ||||||||
Credit agreement, maximum borrowing capacity | $ 325,000,000 | |||||||
Credit agreement, issuance percentage of par | 99.66% | |||||||
Long-term debt | $ 478,100,000 | $ 484,600,000 | ||||||
Line of Credit | Senior Revolver | ||||||||
Debt Instrument [Line Items] | ||||||||
Principle of debt issued | $ 100,000,000 | |||||||
Long-term debt | 70,000,000 | $ 70,000,000 | ||||||
Line of Credit | Line of Credit | ||||||||
Debt Instrument [Line Items] | ||||||||
Long-term debt | 70,000,000 | |||||||
Borrowing availability | 30,000,000 | |||||||
Line of Credit | Incremental Term Loan | ||||||||
Debt Instrument [Line Items] | ||||||||
Additional borrowing capacity | $ 191,100,000 | |||||||
Line of credit, reduction to availability of funds for certain investments, debt prepayments or restricted payments | $ 105,000,000 | |||||||
Line of Credit | Letter of Credit | ||||||||
Debt Instrument [Line Items] | ||||||||
Long-term debt | $ 0 |
Debt - Scheduled Maturities of
Debt - Scheduled Maturities of Long-Term Debt (Details) $ in Millions | Mar. 31, 2021USD ($) |
Debt Disclosure [Abstract] | |
Remainder of 2021 | $ 25.8 |
2022 | 38.7 |
2023 | 45.2 |
2024 | 438.4 |
Total | $ 548.1 |
Share-Based Compensation - Narr
Share-Based Compensation - Narrative (Details) - USD ($) $ in Millions | 3 Months Ended | ||
Mar. 31, 2021 | Mar. 31, 2020 | Mar. 31, 2019 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Share-based compensation expense | $ 12.7 | $ 4.8 | |
Related tax benefits | 2.2 | 0.7 | |
Income tax benefit | $ 2.3 | $ 0.6 | |
PBRSUs | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Maximum exercisable (in shares) | 5,943,470 | ||
Minimum | PBRSUs | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Number of shares vesting if targets conditions met, potential percentage | 0.00% | 0.00% | |
Maximum | PBRSUs | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Number of shares vesting if targets conditions met, potential percentage | 200.00% | 150.00% |
Share-Based Compensation - Comp
Share-Based Compensation - Compensation Expense Allocation (Details) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ||
Total share-based compensation expense | $ 12.7 | $ 4.8 |
Cost of services | ||
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ||
Total share-based compensation expense | 7.3 | 1.9 |
Selling, general and administrative | ||
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ||
Total share-based compensation expense | 5.4 | 2.9 |
Other | ||
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ||
Total share-based compensation expense | $ 0 | $ 0 |
Share-Based Compensation - Assu
Share-Based Compensation - Assumptions (Details) | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Share-based Payment Arrangement [Abstract] | ||
Expected dividend yield | 0.00% | 0.00% |
Risk-free interest rate | 0.40% | 1.70% |
Expected volatility | 43.00% | 43.00% |
Expected term (in years) | 5 years 6 months | 5 years 6 months |
Share-Based Compensation - Stoc
Share-Based Compensation - Stock Option Activity (Details) - $ / shares | 3 Months Ended | |
Mar. 31, 2021 | Dec. 31, 2020 | |
Options | ||
Outstanding at beginning of period (in shares) | 6,220,971 | |
Granted (in shares) | 1,625 | |
Exercised (in shares) | (539,795) | |
Canceled/forfeited (in shares) | (1,040) | |
Expired (in shares) | 0 | |
Outstanding at end of period (in shares) | 5,681,761 | |
Outstanding, vested and exercisable at end of period (in shares) | 4,782,897 | 5,230,690 |
Weighted- Average Exercise Price | ||
Outstanding at beginning of period (in dollars per share) | $ 3.68 | |
Granted (in dollars per share) | 23.49 | |
Exercised (in dollars per share) | 6.47 | |
Canceled/forfeited (in dollars per share) | 3.85 | |
Expired (in dollars per share) | 0 | |
Outstanding at end of period (in dollars per share) | 3.42 | |
Outstanding, vested and exercisable at end of period (in dollars per share) | $ 3.41 | $ 3.73 |
Share-Based Compensation - Othe
Share-Based Compensation - Other Than Stock Options Activity (Details) - USD ($) $ / shares in Units, $ in Millions | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
RSUs | ||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] | ||
Outstanding and unvested at beginning of period (in shares) | 2,108,447 | |
Granted (in shares) | 2,719 | |
Vested (in shares) | (6,497) | |
Forfeited (in shares) | (41,381) | |
Outstanding and unvested at end of period (in shares) | 2,063,288 | |
Weighted- Average Grant Date Fair Value | ||
Outstanding and unvested at beginning of period (in dollars per share) | $ 9.87 | |
Granted (in dollars per share) | 23.77 | |
Vested (in dollars per share) | 10.80 | |
Forfeited (in dollars per share) | 12.99 | |
Outstanding and unvested at end of period (in dollars per share) | $ 9.82 | |
Shares surrendered for taxes (in shares) | 2,201 | 545 |
Cost of shares surrendered for taxes | $ 0 | $ 0 |
PBRSUs | ||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] | ||
Outstanding and unvested at beginning of period (in shares) | 2,917,071 | |
Granted (in shares) | 290,354 | |
Vested (in shares) | 0 | |
Forfeited (in shares) | (646) | |
Outstanding and unvested at end of period (in shares) | 3,206,779 | |
Weighted- Average Grant Date Fair Value | ||
Outstanding and unvested at beginning of period (in dollars per share) | $ 11.35 | |
Granted (in dollars per share) | 25.09 | |
Vested (in dollars per share) | 0 | |
Forfeited (in dollars per share) | 5.34 | |
Outstanding and unvested at end of period (in dollars per share) | $ 12.59 | |
Shares surrendered for taxes (in shares) | 0 | 0 |
Cost of shares surrendered for taxes | $ 0 | $ 0 |
Other Expenses - Schedule of Ot
Other Expenses - Schedule of Other Expenses (Details) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Other Income and Expenses [Abstract] | ||
Severance and related employee benefits | $ 1.5 | $ 1.1 |
Strategic initiatives | 6.5 | 3.2 |
Facility-exit charges | 1.5 | 0.4 |
Other | 3.5 | 4 |
Total other expenses | 13 | 8.7 |
Contingent consideration changes included in strategic initiatives | 0.5 | |
COVID-19 related costs, included in Other | $ 1.7 | $ 2.6 |
Income Taxes - Narrative (Detai
Income Taxes - Narrative (Details) - USD ($) $ in Millions | 3 Months Ended | |||
Mar. 31, 2021 | Mar. 31, 2020 | Dec. 31, 2020 | Apr. 01, 2020 | |
Income Tax Contingency [Line Items] | ||||
Federal statutory tax rate | 21.00% | 21.00% | ||
Statute of limitations minimum | 3 years | |||
Statute of limitations maximum | 6 years | |||
Gross deferred tax assets | $ 146.1 | |||
Deferred tax assets related to operating loss carryforwards | $ 81.6 | |||
SCI Acquisition | ||||
Income Tax Contingency [Line Items] | ||||
Deferred tax assets related to operating loss carryforwards | $ 10.4 | |||
Deferred income tax liabilities, net | 10.9 | $ 10.9 | ||
Deferred tax assets related to research and experimentation credits | $ 3.7 |
8.00% Series A Convertible Pr_3
8.00% Series A Convertible Preferred Stock - Narrative (Details) - USD ($) | Jan. 19, 2021 | Jan. 15, 2021 | Mar. 31, 2021 | Mar. 31, 2020 | Dec. 31, 2020 |
Temporary Equity [Line Items] | |||||
Cash paid, stock conversion (not to exceed) | $ 105,000,000 | $ 0 | |||
Dividends | $ 592,300,000 | $ 5,400,000 | |||
TCP-ASC ACHI Series LLLP | |||||
Temporary Equity [Line Items] | |||||
Cash paid, stock conversion (not to exceed) | $ 105,000,000 | ||||
Redeemable Convertible Preferred Stock | |||||
Temporary Equity [Line Items] | |||||
Number of shares converted (in shares) | 294,266 | ||||
Preferred stock, dividend rate (percentage) | 8.00% | 8.00% | |||
Redeemable Convertible Preferred Stock | TCP-ASC ACHI Series LLLP | |||||
Temporary Equity [Line Items] | |||||
Number of shares converted (in shares) | 294,266 | ||||
Preferred stock, dividend rate (percentage) | 8.00% | 8.00% | |||
Common Stock | TCP-ASC ACHI Series LLLP | |||||
Temporary Equity [Line Items] | |||||
Number of shares issued in stock conversion (in shares) | 117,706,400 | ||||
Additional shares issued (in shares) | 21,582,800 |
8.00% Series A Convertible Pr_4
8.00% Series A Convertible Preferred Stock - Schedule of Preferred Stock Activity (Details) - Redeemable Convertible Preferred Stock $ in Millions | 3 Months Ended |
Mar. 31, 2021USD ($)shares | |
Shares Issued and Outstanding | |
Beginning Balance (in shares) | shares | 288,497 |
Dividends paid/accrued dividends (in shares) | shares | 5,769 |
Conversion of preferred stock (in shares) | shares | (294,266) |
Ending Balance (in shares) | shares | 0 |
Carrying Value | |
Beginning Balance | $ | $ 251.5 |
Dividends paid/accrued dividends | $ | 0 |
Conversion of preferred stock | $ | (251.5) |
Ending Balance | $ | $ 0 |
Earnings (Loss) Per Share - Com
Earnings (Loss) Per Share - Computation of Basic and Diluted Earnings Per Share (Details) - USD ($) $ / shares in Units, $ in Millions | Jan. 19, 2021 | Jan. 15, 2021 | Mar. 31, 2021 | Mar. 31, 2020 | Dec. 31, 2020 |
Basic EPS: | |||||
Net income | $ 25.8 | $ 18.2 | |||
Less dividends on preferred shares | (592.3) | (5.4) | |||
Less income allocated to preferred shareholders | 0 | (6.2) | |||
Net income (loss) available/allocated to common shareholders - basic | (566.5) | 6.6 | |||
Diluted EPS: | |||||
Less income allocated to preferred shareholders | 0 | (5) | |||
Net income (loss) available/(allocated) to common shareholders - diluted | $ (566.5) | $ 7.8 | |||
Basic weighted-average common shares (in shares) | 239,290,145 | 114,441,043 | |||
Add: Effect of dilutive equity awards (in shares) | 0 | 11,893,514 | |||
Add: Effect of dilutive warrants (in shares) | 0 | 43,285,621 | |||
Diluted weighted average common shares (in shares) | 239,290,145 | 169,620,178 | |||
Net income (loss) per common share (basic) (in dollars per share) | $ (2.37) | $ 0.06 | |||
Net income (loss) per common share (diluted) (in dollars per share) | $ (2.37) | $ 0.05 | |||
Redeemable Convertible Preferred Stock | |||||
Diluted EPS: | |||||
Preferred stock, dividend rate (percentage) | 8.00% | 8.00% | |||
TCP-ASC ACHI Series LLLP | Redeemable Convertible Preferred Stock | |||||
Diluted EPS: | |||||
Preferred stock, dividend rate (percentage) | 8.00% | 8.00% |
Earnings (Loss) Per Share - Nar
Earnings (Loss) Per Share - Narrative (Details) - shares | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Antidilutive common share equivalents (in shares) | 13,688,519 | 525,414 |
Warrant | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Dilutive shares (in shares) | 53,206,631 | |
Warrant | Investor's | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Antidilutive common share equivalents (in shares) | 60,000,000 | |
Warrant | Intermountain | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Antidilutive common share equivalents (in shares) | 1,500,000 |
Commitments and Contingencies -
Commitments and Contingencies - Narrative (Details) | Apr. 19, 2021claim |
TCP-ASC Recapitalization Litigation | Pending Litigation | Subsequent Event | |
Loss Contingencies [Line Items] | |
Number of complaints filed | 2 |
Related Party Transactions - Ne
Related Party Transactions - Net Services Revenue (Details) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Related Party Transactions [Abstract] | ||
Ascension | $ 215.5 | $ 208.4 |
Related Party Transactions - Su
Related Party Transactions - Summary Amounts Included in Balance Sheet (Details) - USD ($) $ in Millions | Mar. 31, 2021 | Dec. 31, 2020 |
Related Party Transaction [Line Items] | ||
Accounts receivable, net of $0.1 million and $0.1 million allowance - related party | $ 31.8 | $ 30.9 |
Accounts receivable, allowance - related party | 3.8 | 3.7 |
Ascension | ||
Related Party Transaction [Line Items] | ||
Accounts receivable, net of $0.1 million and $0.1 million allowance - related party | 31.8 | 30.9 |
Accounts receivable, allowance - related party | 0.1 | 0.1 |
Current portion of customer liabilities | 10.6 | 15.3 |
Non-current portion of customer liabilities | 15.4 | 16.3 |
Total customer liabilities | $ 26 | $ 31.6 |
Deferred Contract Costs - Summa
Deferred Contract Costs - Summary of Deferred Contract Costs (Details) - USD ($) $ in Millions | Mar. 31, 2021 | Dec. 31, 2020 |
Capitalized Contract Cost [Line Items] | ||
Total deferred contract costs | $ 24.2 | $ 24.1 |
Prepaid expenses and other current assets | ||
Capitalized Contract Cost [Line Items] | ||
Total deferred contract costs | 4.7 | 4.5 |
Other assets | ||
Capitalized Contract Cost [Line Items] | ||
Total deferred contract costs | $ 19.5 | $ 19.6 |
Deferred Contract Costs - Narra
Deferred Contract Costs - Narrative (Details) - USD ($) | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Revenue from Contract with Customer [Abstract] | ||
Capitalized contract cost, amortization | $ 1,200,000 | $ 1,100,000 |
Impairment losses | $ 0 | $ 0 |
Segments and Customer Concent_2
Segments and Customer Concentrations - Narrative (Details) - segment | 3 Months Ended | 12 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | Dec. 31, 2020 | |
Segment Reporting Information [Line Items] | |||
Number of operating segments | 1 | ||
Number of reportable segments | 1 | ||
Customer Concentration Risk | Revenue | Ascension | |||
Segment Reporting Information [Line Items] | |||
Concentration percentage | 63.00% | 65.00% | |
Customer Concentration Risk | Revenue | Intermountain Healthcare | |||
Segment Reporting Information [Line Items] | |||
Concentration percentage | 14.00% | 15.00% | |
Customer Concentration Risk | Accounts Receivable | Ascension | |||
Segment Reporting Information [Line Items] | |||
Concentration percentage | 25.00% | 25.00% |
Derivative Financial Instrume_2
Derivative Financial Instruments - Narrative (Details) - Designated as Hedging Instrument - Cash Flow Hedging - USD ($) | 3 Months Ended | ||
Mar. 31, 2021 | Mar. 31, 2020 | Dec. 31, 2020 | |
Foreign Currency Hedges | |||
Derivative [Line Items] | |||
Gains (losses) reported in accumulated other comprehensive income | $ 600,000 | ||
Gains (losses) to be reclassified within next 12 months | 600,000 | ||
Derivatives, net gain (loss) reclassified into cost of services | 400,000 | $ (100,000) | |
Notional amount | 95,100,000 | $ 55,900,000 | |
Interest Rate Swap | |||
Derivative [Line Items] | |||
Gains (losses) reported in accumulated other comprehensive income | (1,800,000) | ||
Gains (losses) to be reclassified within next 12 months | (1,300,000) | ||
Derivatives, net gain (loss) reclassified into cost of services | (500,000) | $ 100,000 | |
Notional amount | $ 100,000,000 | $ 200,000,000 |
Subsequent Events - Narrative (
Subsequent Events - Narrative (Details) - Subsequent Event - VisitPay - USD ($) | 3 Months Ended | |
Sep. 30, 2021 | May 03, 2021 | |
Bank of America | ||
Subsequent Event [Line Items] | ||
Debt refinancing commitment letter obtained | $ 300,000,000 | |
Forecast | ||
Subsequent Event [Line Items] | ||
Purchase consideration | $ 298,000,000 | |
Financing condition linked to consummation of the acquisition | $ 0 |